<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2017.01759</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Stability-Diversity Tradeoffs Impose Fundamental Constraints on Selection of Synthetic Human V<sub>H</sub>/V<sub>L</sub> Single-Domain Antibodies from <italic>In Vitro</italic> Display Libraries</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Henry</surname> <given-names>Kevin A.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/142766"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname> <given-names>Dae Young</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kandalaft</surname> <given-names>Hiba</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lowden</surname> <given-names>Michael J.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yang</surname> <given-names>Qingling</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schrag</surname> <given-names>Joseph D.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hussack</surname> <given-names>Greg</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/388306"/>
</contrib>
<contrib contrib-type="author">
<name><surname>MacKenzie</surname> <given-names>C. Roger</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/357207"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Tanha</surname> <given-names>Jamshid</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x0002A;</xref>
<uri xlink:href="http://frontiersin.org/people/u/386507"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Human Health Therapeutics Research Centre, National Research Council Canada</institution>, <addr-line>Ottawa, ON</addr-line>, <country>Canada</country></aff>
<aff id="aff2"><sup>2</sup><institution>Human Health Therapeutics Research Centre, National Research Council Canada</institution>, <addr-line>Montr&#x000E9;al, QC</addr-line>, <country>Canada</country></aff>
<aff id="aff3"><sup>3</sup><institution>School of Environmental Sciences, University of Guelph</institution>, <addr-line>Guelph, ON</addr-line>, <country>Canada</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Biochemistry, Microbiology and Immunology, University of Ottawa</institution>, <addr-line>Ottawa, ON</addr-line>, <country>Canada</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Abdul Qader Abbady, Atomic Energy Commission of Syria, Syria</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Serge Muyldermans, Vrije Universiteit Brussel, Belgium; Oscar R. Burrone, International Centre for Genetic Engineering and Biotechnology, Italy</p></fn>
<corresp content-type="corresp" id="cor1">&#x0002A;Correspondence: Jamshid Tanha, <email>jamshid.tanha&#x00040;nrc-cnrc.gc.ca</email></corresp>
<fn fn-type="other" id="fn001"><p>This is NRC-HHT publication number: 53364.</p></fn>
<fn fn-type="other" id="fn002"><p>Specialty section: This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>12</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>1759</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>09</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>11</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2015 Her Majesty the Queen in Right of Canada.</copyright-statement>
<copyright-year>2015</copyright-year>
<copyright-holder>Her Majesty the Queen in Right of Canada</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Human autonomous V<sub>H</sub>/V<sub>L</sub> single-domain antibodies (sdAbs) are attractive therapeutic molecules, but often suffer from suboptimal stability, solubility and affinity for cognate antigens. Most commonly, human sdAbs have been isolated from <italic>in vitro</italic> display libraries constructed <italic>via</italic> synthetic randomization of rearranged V<sub>H</sub>/V<sub>L</sub> domains. Here, we describe the design and characterization of three novel human V<sub>H</sub>/V<sub>L</sub> sdAb libraries through a process of: (i) exhaustive biophysical characterization of 20 potential V<sub>H</sub>/V<sub>L</sub> sdAb library scaffolds, including assessment of expression yield, aggregation resistance, thermostability and tolerance to complementarity-determining region (CDR) substitutions; (ii) <italic>in vitro</italic> randomization of the CDRs of three V<sub>H</sub>/V<sub>L</sub> sdAb scaffolds, with tailored amino acid representation designed to promote solubility and expressibility; and (iii) systematic benchmarking of the three V<sub>H</sub>/V<sub>L</sub> libraries by panning against five model antigens. We isolated &#x02265;1 antigen-specific human sdAb against four of five targets (13 V<sub>H</sub>s and 7 V<sub>L</sub>s in total); these were predominantly monomeric, had antigen-binding affinities ranging from 5&#x02009;nM to 12&#x02009;&#x000B5;M (average: 2&#x02013;3&#x02009;&#x000B5;M), but had highly variable expression yields (range: 0.1&#x02013;19&#x02009;mg/L). Despite our efforts to identify the most stable V<sub>H</sub>/V<sub>L</sub> scaffolds, selection of antigen-specific binders from these libraries was unpredictable (overall success rate for all library-target screens: &#x0007E;53%) with a high attrition rate of sdAbs exhibiting false positive binding by ELISA. By analyzing V<sub>H</sub>/V<sub>L</sub> sdAb library sequence composition following selection for monomeric antibody expression (binding to protein A/L followed by amplification in bacterial cells), we found that some V<sub>H</sub>/V<sub>L</sub> sdAbs had marked growth advantages over others, and that the amino acid composition of the CDRs of this set of sdAbs was dramatically restricted (bias toward Asp and His and away from aromatic and hydrophobic residues). Thus, CDR sequence clearly dramatically impacts the stability of human autonomous V<sub>H</sub>/V<sub>L</sub> immunoglobulin domain folds, and sequence-stability tradeoffs must be taken into account during the design of such libraries.</p>
</abstract>
<kwd-group>
<kwd>single-domain antibody</kwd>
<kwd>synthetic antibody</kwd>
<kwd>human V<sub>H</sub>/V<sub>L</sub></kwd>
<kwd>phage display</kwd>
<kwd>protein engineering</kwd>
</kwd-group>
<contract-sponsor id="cn01">National Research Council Canada<named-content content-type="fundref-id">10.13039/501100000046</named-content></contract-sponsor>
<counts>
<fig-count count="5"/>
<table-count count="4"/>
<equation-count count="0"/>
<ref-count count="61"/>
<page-count count="15"/>
<word-count count="9324"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="introduction">
<title>Introduction</title>
<p>The concept of an autonomous single immunoglobulin variable domain (single-domain antibodies or sdAbs) as the smallest representation of an antigen-binding-competent antibody was first described by Ward et al. in the mouse (<xref ref-type="bibr" rid="B1">1</xref>). With the discovery of naturally occurring heavy chain-only antibodies in <italic>Camelidae</italic> (<xref ref-type="bibr" rid="B2">2</xref>) and in cartilaginous sharks (<xref ref-type="bibr" rid="B3">3</xref>) several years later (the single variable domains of which can recognize antigen autonomously), it became clear that sdAbs represented not only a theoretical possibility but a viable immunological solution to the problem of antigen recognition. Although the human humoral immune system produces only conventional antibodies with paired heavy and light chains and not sdAbs, the question of whether human sdAbs (autonomous variable heavy- or light-chain domains, V<sub>H</sub>s or V<sub>L</sub>s) could be isolated and/or molecularly engineered <italic>in vitro</italic> was brought to light.</p>
<p>The identification, engineering and biophysical characterization of a handful of non-antigen-specific human V<sub>H</sub>/V<sub>L</sub> sdAbs has been extensively reported and discussed (<xref ref-type="bibr" rid="B4">4</xref>). The first efforts to produce human V<sub>H</sub>/V<sub>L</sub> sdAbs with novel antigen-binding specificities used &#x0201C;camelized&#x0201D; scaffolds that incorporated the solubilizing framework region (FR) substitutions found in camelid sdAbs (<xref ref-type="bibr" rid="B5">5</xref>&#x02013;<xref ref-type="bibr" rid="B9">9</xref>). Although this approach yielded antigen-specific sdAbs with excellent solubility and biophysical properties, it relied on undesirable sequence deviation from the human IGHV germline. Later, rare fully human rearranged V<sub>H</sub> and V<sub>L</sub> variable domains were discovered that were autonomously stable and monomeric and large phage display libraries were constructed by randomizing their complementarity-determining regions (CDRs), although it was clear from the mid-2000s that certain CDR sequences (potentially low in hydrophobic content and rich in negative charge) were better compatible with solubility and stability of these molecules (<xref ref-type="bibr" rid="B9">9</xref>&#x02013;<xref ref-type="bibr" rid="B11">11</xref>). There are now many examples of fully human antibodies (primarily V<sub>H</sub>s) isolated from such libraries against a variety of targets, including &#x003B1;-amylase (<xref ref-type="bibr" rid="B12">12</xref>), &#x003B2;-galactosidase (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>), <italic>Candida albicans</italic> MP65 and SAP-2 (<xref ref-type="bibr" rid="B15">15</xref>), carbonic anhydrase (<xref ref-type="bibr" rid="B12">12</xref>), CD154 (<xref ref-type="bibr" rid="B16">16</xref>), CD28 (<xref ref-type="bibr" rid="B17">17</xref>), CD40 (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>), CD40L (<xref ref-type="bibr" rid="B20">20</xref>), <italic>Clostridium difficile</italic> toxin B (<xref ref-type="bibr" rid="B21">21</xref>), EGFR (<xref ref-type="bibr" rid="B22">22</xref>), glypican-2 (<xref ref-type="bibr" rid="B23">23</xref>), glypican-3 (<xref ref-type="bibr" rid="B24">24</xref>), human serum albumin (HSA) (<xref ref-type="bibr" rid="B25">25</xref>&#x02013;<xref ref-type="bibr" rid="B27">27</xref>), lysozyme (<xref ref-type="bibr" rid="B28">28</xref>&#x02013;<xref ref-type="bibr" rid="B30">30</xref>), maltose-binding protein (<xref ref-type="bibr" rid="B31">31</xref>), MDM4 (<xref ref-type="bibr" rid="B32">32</xref>), mesothelin (<xref ref-type="bibr" rid="B33">33</xref>), TNF-&#x003B1; (<xref ref-type="bibr" rid="B34">34</xref>), TNFR1 (<xref ref-type="bibr" rid="B35">35</xref>), and VEGF (<xref ref-type="bibr" rid="B22">22</xref>). These fully human V<sub>H</sub>/V<sub>L</sub> sdAbs exhibit a variety of antigen-binding modes and functional activities and several have entered clinical development, where they have been generally well-tolerated albeit unexpectedly immunogenic (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>).</p>
<p>Here, we report the design, construction and characterization of three novel phage-displayed, synthetically randomized human V<sub>H</sub>/V<sub>L</sub> sdAb libraries. We attempted to circumvent the unfavorable biophysical properties of many human V<sub>H</sub>/V<sub>L</sub> sdAbs by (i) selecting ultra-stable V<sub>H</sub>/V<sub>L</sub> sdAbs tolerant to CDR modification as library scaffolds, (ii) maximizing randomized sequence diversity in CDRs using trinucleotide mutagenesis, and (iii) spiking the library with negatively charged residues to encourage solubility. Similarly to the experiences of others, we were able to isolate monomeric, high-affinity V<sub>H</sub>/V<sub>L</sub> sdAbs from the libraries against some antigens but not against others. The stochastic process of selecting binders from human V<sub>H</sub>/V<sub>L</sub> sdAb libraries is likely a consequence of fundamental tradeoffs between CDR sequence and human V<sub>H</sub>/V<sub>L</sub> sdAb stability and aggregation resistance.</p>
</sec>
<sec id="S2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="S2-1">
<title>Identification of Human Autonomous V<sub>H</sub>/V<sub>L</sub> sdAb Scaffolds</title>
<p>The human autonomous V<sub>H</sub> and V<sub>L</sub> sdAb scaffolds used in this study (Table <xref ref-type="table" rid="T1">1</xref>; Figure S1 in Supplementary Material) were isolated as previously described by To et al. (<xref ref-type="bibr" rid="B38">38</xref>) and Kim et al. (<xref ref-type="bibr" rid="B39">39</xref>). Disulfide-stabilized versions of each V<sub>H</sub>/V<sub>L</sub> sdAb (bearing an intradomain disulfide linkage formed between Cys residues at IMGT positions 54 and 78) were produced by overlap extension PCR as described in Kim et al. (<xref ref-type="bibr" rid="B40">40</xref>).</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Properties of human V<sub>H</sub> and V<sub>L</sub> single-domain antibody scaffolds used in this study.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Type</th>
<th valign="top" align="left">Scaffold<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></th>
<th valign="top" align="center">Disulfide linkages<xref ref-type="table-fn" rid="tfn2"><sup>b</sup></xref></th>
<th valign="top" align="center">Germline rearrangement</th>
<th valign="top" align="center">CDR3 length (aa)</th>
<th valign="top" align="center"><italic>T</italic><sub>m</sub> (&#x000B0;C)</th>
<th valign="top" align="center">Monomer (%)</th>
<th valign="top" align="center">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="10">V<sub>L</sub></td>
<td align="left" valign="top">VL383</td>
<td align="center" valign="top">23&#x02013;104</td>
<td align="center" valign="top">IGKV3-20&#x02013;IGKJ2</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">57.3</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="B39">39</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">VL383<sub>SS</sub></td>
<td align="center" valign="top">23&#x02013;104, 54&#x02013;78</td>
<td align="center" valign="top">IGKV3-20&#x02013;IGKJ2</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">73.7</td>
<td align="center" valign="top">85.3</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">VL382</td>
<td align="center" valign="top">23&#x02013;104</td>
<td align="center" valign="top">IGKV3-20&#x02013;IGKJ1</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">70.1</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="B39">39</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">VL382<sub>SS</sub></td>
<td align="center" valign="top">23&#x02013;104, 54&#x02013;78</td>
<td align="center" valign="top">IGKV3-20&#x02013;IGKJ1</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">83.3</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">VL335</td>
<td align="center" valign="top">23&#x02013;104</td>
<td align="center" valign="top">IGKV3-20&#x02013;IGKJ1</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">61.7</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="B39">39</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">VL335<sub>SS</sub></td>
<td align="center" valign="top">23&#x02013;104, 54&#x02013;78</td>
<td align="center" valign="top">IGKV3-20&#x02013;IGKJ1</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">79.0</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="B39">39</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">VL330</td>
<td align="center" valign="top">23&#x02013;104</td>
<td align="center" valign="top">IGKV1-39&#x02013;IGKJ2</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">62.8</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="B39">39</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">VL330<sub>SS</sub></td>
<td align="center" valign="top">23&#x02013;104, 54&#x02013;78</td>
<td align="center" valign="top">IGKV1-39&#x02013;IGKJ2</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">83.7</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">VL325</td>
<td align="center" valign="top">23&#x02013;104</td>
<td align="center" valign="top">IGKV3-11&#x02013;IGKJ4</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">68.5</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="B39">39</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">VL325<sub>SS</sub></td>
<td align="center" valign="top">23&#x02013;104, 54&#x02013;78</td>
<td align="center" valign="top">IGKV3-11&#x02013;IGKJ4</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">82.5</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="B39">39</xref>)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="10">V<sub>H</sub></td>
<td align="left" valign="top">VH420</td>
<td align="center" valign="top">23&#x02013;104</td>
<td align="center" valign="top">IGHV3-15&#x02013;IGHJ4</td>
<td align="center" valign="top">10</td>
<td align="center" valign="top">57.8</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="B38">38</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">VH420<sub>SS</sub></td>
<td align="center" valign="top">23&#x02013;104, 54&#x02013;78</td>
<td align="center" valign="top">IGHV3-15&#x02013;IGHJ4</td>
<td align="center" valign="top">10</td>
<td align="center" valign="top">67.3</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">VH428</td>
<td align="center" valign="top">23&#x02013;104</td>
<td align="center" valign="top">IGHV3-49&#x02013;IGHJ4</td>
<td align="center" valign="top">14</td>
<td align="center" valign="top">62.3</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="B38">38</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">VH428<sub>SS</sub></td>
<td align="center" valign="top">23&#x02013;104, 54&#x02013;78</td>
<td align="center" valign="top">IGHV3-49&#x02013;IGHJ4</td>
<td align="center" valign="top">14</td>
<td align="center" valign="top">73.1</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">VH429</td>
<td align="center" valign="top">23&#x02013;104</td>
<td align="center" valign="top">IGHV3-23&#x02013;IGHJ4</td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">58.5</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="B38">38</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">VH429<sub>SS</sub></td>
<td align="center" valign="top">23&#x02013;104, 54&#x02013;78</td>
<td align="center" valign="top">IGHV3-23&#x02013;IGHJ4</td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">71.8</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">VHB82</td>
<td align="center" valign="top">23&#x02013;104</td>
<td align="center" valign="top">IGHV3-23&#x02013;IGHJ6</td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">57.9</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="B38">38</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">VHB82<sub>SS</sub></td>
<td align="center" valign="top">23&#x02013;104, 54&#x02013;78</td>
<td align="center" valign="top">IGHV3-23&#x02013;IGHJ6</td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">72.9</td>
<td align="center" valign="top">80.8</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">VHM81</td>
<td align="center" valign="top">23&#x02013;104</td>
<td align="center" valign="top">IGHV3-23&#x02013;IGHJ3</td>
<td align="center" valign="top">14</td>
<td align="center" valign="top">66.9</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">(<xref ref-type="bibr" rid="B38">38</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">VHM81<sub>SS</sub></td>
<td align="center" valign="top">23&#x02013;104, 54&#x02013;78</td>
<td align="center" valign="top">IGHV3-23&#x02013;IGHJ3</td>
<td align="center" valign="top">14</td>
<td align="center" valign="top">76.8</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1"><p><italic><sup>a</sup>Full-length amino acid sequences are listed in Figure S1 in Supplementary Material</italic>.</p></fn>
<fn id="tfn2"><p><italic><sup>b</sup>IMGT numbering</italic>.</p></fn></table-wrap-foot></table-wrap>
</sec>
<sec id="S2-2">
<title>CDR Shuffling</title>
<p>All three CDRs of each V<sub>H</sub>/V<sub>L</sub> scaffold were simultaneously exchanged for those listed in Table <xref ref-type="table" rid="T2">2</xref> (20 V<sub>H</sub>/V<sub>L</sub> scaffolds&#x02009;&#x000D7;&#x02009;12 CDR sets&#x02009;&#x0003D;&#x02009;240 CDR-shuffled variants). DNA constructs encoding the CDR-shuffled variants were synthesized commercially (GeneArt/Life Technologies, Regensberg, Germany) and subcloned into the pSJF2H bacterial expression vector (<xref ref-type="bibr" rid="B12">12</xref>).</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Amino acid sequences of complementarity-determining region (CDR) sets introduced into human V<sub>H</sub>/V<sub>L</sub> single-domain antibody (sdAb) scaffolds for biophysical stability assessment.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">V<sub>L</sub> CDR set</th>
<th valign="top" align="left">CDR-L1<xref ref-type="table-fn" rid="tfn3"><sup>a</sup></xref></th>
<th valign="top" align="left">CDR-L2<xref ref-type="table-fn" rid="tfn4"><sup>b</sup></xref></th>
<th valign="top" align="left">CDR-L3<xref ref-type="table-fn" rid="tfn5"><sup>c</sup></xref></th>
<th valign="top" align="center">CDR-L3 length (aa)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">1</td>
<td align="left" valign="top">RASQSVLVHLA</td>
<td align="left" valign="top">GDSYRAD</td>
<td align="left" valign="top">QQTFYPST</td>
<td align="center" valign="top">8</td>
</tr>
<tr>
<td align="left" valign="top">2</td>
<td align="left" valign="top">RASQSVISNLA</td>
<td align="left" valign="top">GDSFRAF</td>
<td align="left" valign="top">QQVAHPTT</td>
<td align="center" valign="top">8</td>
</tr>
<tr>
<td align="left" valign="top">3</td>
<td align="left" valign="top">RASQSVTDTLLA</td>
<td align="left" valign="top">GISHRAD</td>
<td align="left" valign="top">QQLVHPFT</td>
<td align="center" valign="top">8</td>
</tr>
<tr>
<td align="left" valign="top">4</td>
<td align="left" valign="top">RASQSVVHNLA</td>
<td align="left" valign="top">GLSTRAH</td>
<td align="left" valign="top">QQFDHPYT</td>
<td align="center" valign="top">8</td>
</tr>
<tr>
<td align="left" valign="top">5</td>
<td align="left" valign="top">RASQSVSSNLA</td>
<td align="left" valign="top">GASLRAT</td>
<td align="left" valign="top">QQYLIPPAT</td>
<td align="center" valign="top">9</td>
</tr>
<tr>
<td align="left" valign="top">6</td>
<td align="left" valign="top">RASQSVAPSLLA</td>
<td align="left" valign="top">GTSTRAP</td>
<td align="left" valign="top">QQPTLFPTT</td>
<td align="center" valign="top">9</td>
</tr>
<tr>
<td align="left" valign="top">7</td>
<td align="left" valign="top">RASQSVNLPYLA</td>
<td align="left" valign="top">GVSTRAY</td>
<td align="left" valign="top">QQIAVTPYT</td>
<td align="center" valign="top">9</td>
</tr>
<tr>
<td align="left" valign="top">8</td>
<td align="left" valign="top">RASQSVDYNLA</td>
<td align="left" valign="top">DISFRAN</td>
<td align="left" valign="top">QQSLSPPAT</td>
<td align="center" valign="top">9</td>
</tr>
<tr>
<td align="left" valign="top">9</td>
<td align="left" valign="top">RASQSVNITSLA</td>
<td align="left" valign="top">GTSTRAD</td>
<td align="left" valign="top">QQTNTHHPVT</td>
<td align="center" valign="top">10</td>
</tr>
<tr>
<td align="left" valign="top">10</td>
<td align="left" valign="top">RASQSVSSYLA</td>
<td align="left" valign="top">GLSLRAV</td>
<td align="left" valign="top">QQTDSFFPFT</td>
<td align="center" valign="top">10</td>
</tr>
<tr>
<td align="left" valign="top">11</td>
<td align="left" valign="top">RASQSVPIVLA</td>
<td align="left" valign="top">GHSLRAD</td>
<td align="left" valign="top">QQLAFFDPFT</td>
<td align="center" valign="top">10</td>
</tr>
<tr>
<td align="left" valign="top">12</td>
<td align="left" valign="top">RASQSVYLNLA</td>
<td align="left" valign="top">GVSVRAD</td>
<td align="left" valign="top">QQILLFYPHT</td>
<td align="center" valign="top">10</td>
</tr>
<tr>
<td align="left" valign="top" colspan="5"><hr/></td>
</tr>
<tr>
<td align="left" valign="top"><bold>V<sub>H</sub> CDR set</bold></td>
<td align="left" valign="top"><bold>CDR-H1<xref ref-type="table-fn" rid="tfn6"><sup>d</sup></xref></bold></td>
<td align="left" valign="top"><bold>CDR-H2<xref ref-type="table-fn" rid="tfn7"><sup>e</sup></xref></bold></td>
<td align="left" valign="top"><bold>CDR-H3<xref ref-type="table-fn" rid="tfn8"><sup>f</sup></xref></bold></td>
<td align="center" valign="top"><bold>CDR-H3 length (aa)</bold></td>
</tr>
<tr>
<td align="left" valign="top">1</td>
<td align="left" valign="top">SNAWMS</td>
<td align="left" valign="top">RITSKTDGGTTD</td>
<td align="left" valign="top">DQANAFDI</td>
<td align="center" valign="top">8</td>
</tr>
<tr>
<td align="left" valign="top">2</td>
<td align="left" valign="top">DGYAMH</td>
<td align="left" valign="top">VTNNGGSTS</td>
<td align="left" valign="top">QSITGPTGAFDI</td>
<td align="center" valign="top">12</td>
</tr>
<tr>
<td align="left" valign="top">3</td>
<td align="left" valign="top">SSYAMS</td>
<td align="left" valign="top">AISGGGDHTY</td>
<td align="left" valign="top">EGMVRGVSSAPFDY</td>
<td align="center" valign="top">14</td>
</tr>
<tr>
<td align="left" valign="top">4</td>
<td align="left" valign="top">ISESMT</td>
<td align="left" valign="top">AISSSGGSTY</td>
<td align="left" valign="top">KKIDGARYDY</td>
<td align="center" valign="top">10</td>
</tr>
<tr>
<td align="left" valign="top">5</td>
<td align="left" valign="top">NTLSMG</td>
<td align="left" valign="top">AVSRSGGSTY</td>
<td align="left" valign="top">AATKSNTTAYRLSFDY</td>
<td align="center" valign="top">16</td>
</tr>
<tr>
<td align="left" valign="top">6</td>
<td align="left" valign="top">SMYRMG</td>
<td align="left" valign="top">VITRNGSSTY</td>
<td align="left" valign="top">TSGSSYLDAAHVYDY</td>
<td align="center" valign="top">15</td>
</tr>
<tr>
<td align="left" valign="top">7</td>
<td align="left" valign="top">SMDPMA</td>
<td align="left" valign="top">AGSSTGRTTY</td>
<td align="left" valign="top">APYGANWYRDEYAY</td>
<td align="center" valign="top">14</td>
</tr>
<tr>
<td align="left" valign="top">8</td>
<td align="left" valign="top">SRYPVA</td>
<td align="left" valign="top">VISSTGTSTY</td>
<td align="left" valign="top">NSQRTRLQDPNEYDY</td>
<td align="center" valign="top">15</td>
</tr>
<tr>
<td align="left" valign="top">9</td>
<td align="left" valign="top">SNRNMG</td>
<td align="left" valign="top">GISWGGGSTR</td>
<td align="left" valign="top">EFGHNIATSSDEYDY</td>
<td align="center" valign="top">15</td>
</tr>
<tr>
<td align="left" valign="top">10</td>
<td align="left" valign="top">NFYAMS</td>
<td align="left" valign="top">GVSRDGLTTL</td>
<td align="left" valign="top">VITGVWNKVDVNSRSYHY</td>
<td align="center" valign="top">18</td>
</tr>
<tr>
<td align="left" valign="top">11</td>
<td align="left" valign="top">SPTAMG</td>
<td align="left" valign="top">HITWSRGTTR</td>
<td align="left" valign="top">STFLRILPEESAYTY</td>
<td align="center" valign="top">15</td>
</tr>
<tr>
<td align="left" valign="top">12</td>
<td align="left" valign="top">DNYAMA</td>
<td align="left" valign="top">TIDWGDGGAR</td>
<td align="left" valign="top">ARQSRVNLDVARYDY</td>
<td align="center" valign="top">15</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn3"><p><italic><sup>a</sup>IMGT positions 24&#x02013;40 in the acceptor sdAb were replaced with the indicated sequence</italic>.</p></fn>
<fn id="tfn4"><p><italic><sup>b</sup>IMGT positions 56&#x02013;69 in the acceptor sdAb were replaced with the indicated sequence</italic>.</p></fn>
<fn id="tfn5"><p><italic><sup>c</sup>IMGT positions 105&#x02013;117 in the acceptor sdAb were replaced with the indicated sequence</italic>.</p></fn>
<fn id="tfn6"><p><italic><sup>d</sup>IMGT positions 35&#x02013;40 in the acceptor sdAb were replaced with the indicated sequence</italic>.</p></fn>
<fn id="tfn7"><p><italic><sup>e</sup>IMGT positions 55&#x02013;66 in the acceptor sdAb were replaced with the indicated sequence</italic>.</p></fn>
<fn id="tfn8"><p><italic><sup>f</sup>IMGT positions 105&#x02013;117 in the acceptor sdAb were replaced with the indicated sequence</italic>.</p></fn></table-wrap-foot></table-wrap>
</sec>
<sec id="S2-3">
<title>Design and Construction of Synthetic Human V<sub>H</sub>/V<sub>L</sub> sdAb Phage Display Libraries</title>
<p>Three phage-displayed sdAb libraries were constructed by <italic>in vitro</italic> randomization of the sdAb scaffolds VH428, VHB82<sub>SS</sub> and VL383<sub>SS</sub>. Briefly, nondegenerate oligonucleotides spanning each sdAb were chemically synthesized using the phosphoramidite method (GeneArt/Life Technologies) and purified by HPLC. CDRs were randomized <italic>via</italic> incorporation of defined mixtures of trinucleotide phosphoramidite building blocks (<xref ref-type="bibr" rid="B41">41</xref>) during oligonucleotide synthesis. Oligonucleotides were assembled without amplification by Klenow fragment extension, gel purified using a GeneJET&#x02122; gel extraction kit (Thermo-Fisher, Waltham, MA, USA) according to the manufacturer&#x02019;s instructions, and resuspended in a total volume of 1&#x02009;mL TE buffer (10&#x02009;mM Tris-HCl, 1&#x02009;mM EDTA, pH 8.0). Non-amplified library DNA was quantified by real-time PCR using Fast SYBR&#x02122; Green master mix (Thermo-Fisher), and a StepOnePlus&#x02122; real-time PCR system (Thermo-Fisher), then approximately 232&#x02013;1,069&#x02009;ng (4.3&#x02009;&#x000D7;&#x02009;10<sup>11</sup> to 1.5&#x02009;&#x000D7;&#x02009;10<sup>12</sup> molecules) of DNA was PCR-amplified with Phusion<sup>&#x000AE;</sup> high-fidelity DNA polymerase (Thermo-Fisher) using M13F and M13R primers (sequences in Table S1 in Supplementary Material), gel purified using a GeneJET&#x02122; gel extraction kit, then digested and ligated between the <italic>Nco</italic>I and <italic>Not</italic>I sites of the phagemid vector pMED1 (<xref ref-type="bibr" rid="B42">42</xref>). <italic>Escherichia coli</italic> TG1 cells were transformed with the ligation products by electroporation, yielding final library sizes between 1.0&#x02009;&#x000D7;&#x02009;10<sup>10</sup> and 2.3&#x02009;&#x000D7;&#x02009;10<sup>10</sup> independent transformants, &#x02265;95% of which carried V<sub>H</sub>/V<sub>L</sub> sdAb inserts as shown by colony PCR.</p>
</sec>
<sec id="S2-4">
<title>Antibodies, Proteins and Reagents</title>
<p>Recombinant human CEACAM6 (residues 145&#x02013;232) and mouse GITR (residues 20&#x02013;153) ectodomains were produced by transient transfection of HEK293-6E cells as previously described (<xref ref-type="bibr" rid="B43">43</xref>). HSA was from Sigma-Aldrich (St. Louis, MO, USA; Cat. No. A9511). Recombinant human CTLA4 ectodomain (residues 1&#x02013;162) was from Sino Biological (Beijing, China; Cat. No. 11159-H08H). <italic>E. coli</italic> 0157:H7 intimin (residues 658&#x02013;934) fused C-terminally to maltose-binding protein (MBP-intimin) was from GenScript (Piscataway, NJ, USA). Horseradish peroxidase-conjugated antibodies used in ELISA (mouse anti-M13, Cat. No. 27942101; mouse anti-c-Myc, Cat. No. 11814150001; rabbit anti-6&#x02009;&#x000D7;&#x02009;His, Cat. No. A190-114P) were from GE Healthcare (Piscataway, NJ, USA), Bethyl Laboratories (Montgomery, TX, USA) and Roche Diagnostics (Basel, Switzerland), respectively. M13K07 helper phage was from New England BioLabs (Ipswich, MA, USA) and M13K07&#x00394;pIII hyper phage was from Progen Biotechnik (Heidelberg, Germany).</p>
</sec>
<sec id="S2-5">
<title>Isolation of Antigen-Specific Human V<sub>H</sub>/V<sub>L</sub> sdAbs by Panning</title>
<p>Phage particles displaying monovalent V<sub>H</sub>/V<sub>L</sub> sdAbs were prepared by rescue of the three synthetic human V<sub>H</sub>/V<sub>L</sub> sdAb phagemid libraries with M13K07 helper phage as previously described (<xref ref-type="bibr" rid="B42">42</xref>). Briefly, 2&#x02009;&#x000D7;&#x02009;YT broth (4&#x02009;L) containing 1% (w/v) glucose and 100&#x02009;&#x000B5;g/mL ampicillin was inoculated with 1&#x02009;mL phagemid-bearing <italic>E. coli</italic> TG1 cells (7.3&#x02009;&#x000D7;&#x02009;10<sup>10</sup> to 1.6&#x02009;&#x000D7;&#x02009;10<sup>11</sup>) and grown at 37&#x000B0;C with 250&#x02009;rpm shaking to an OD<sub>600</sub> of 0.5. Phagemid-bearing cells were superinfected with M13K07 helper phage at a multiplicity of infection of 20:1 at 37&#x000B0;C for 30&#x02009;min with no shaking, then pelleted and resuspended in 6&#x02009;L of 2&#x02009;&#x000D7;&#x02009;YT broth containing 100&#x02009;&#x000B5;g/mL ampicillin and 50&#x02009;&#x000B5;g/mL kanamycin. The next day, phage particles were purified from bacterial supernatants using two rounds of polyethylene glycol precipitation; neither heat treatment nor filtration steps were used to remove residual bacterial cells. For panning, 5&#x02009;&#x000B5;g of each protein in 35&#x02009;&#x000B5;L phosphate-buffered saline (PBS), pH 7.4, was adsorbed overnight at 4&#x000B0;C in wells of NUNC MaxiSorp&#x02122; 96-well microtiter plates (Thermo-Fisher). The next day, wells were blocked with 200&#x02009;&#x000B5;L PBS containing either 2% (w/v) bovine serum albumin (BSA) or 2% (w/v) skim milk for 1&#x02009;h at 37&#x000B0;C, then rinsed 3&#x02009;&#x000D7; with PBS. Approximately 5&#x02009;&#x000D7;&#x02009;10<sup>11</sup> infective library phage particles (5&#x02009;&#x000D7;&#x02009;10<sup>12</sup> virions) were added to wells in 100&#x02009;&#x000B5;L of PBS containing 1% BSA or skim milk and 0.1% (v/v) Tween-20 for 2&#x02009;h at room temperature. The blocking protein (BSA and skim milk) was switched in alternate rounds of panning, except for panning on HSA in which only skim milk was used. Wells were washed 5&#x02009;&#x000D7; with PBS containing 0.1% Tween-20, 2&#x02009;&#x000D7; with PBS and then bound phage were eluted for 10&#x02009;min with 50&#x02009;&#x000B5;L of 100&#x02009;mM triethylamine, neutralized with 50&#x02009;&#x000B5;L 1&#x02009;M Tris-HCl, pH 7.5, and used to reinfect exponentially growing <italic>E. coli</italic> TG1 cells. The cultures were superinfected with M13K07 helper phage. The next day, amplified phage were purified by polyethylene glycol precipitation from 10&#x02009;mL overnight cultures and used in subsequent panning rounds. After four or five rounds of selection, antigen-specific V<sub>H</sub>- or V<sub>L</sub>-displaying phage clones were identified by their binding in polyclonal and monoclonal phage ELISA as previously described (<xref ref-type="bibr" rid="B42">42</xref>).</p>
</sec>
<sec id="S2-6">
<title>Selection for Monomeric and Expressible Human V<sub>H</sub>/V<sub>L</sub> sdAbs by Panning</title>
<p>Phage particles displaying monovalent V<sub>H</sub>/V<sub>L</sub> sdAbs were prepared by rescue of phagemid libraries with M13K07 helper phage as described above. Phage particles displaying multivalent V<sub>H</sub>/V<sub>L</sub> sdAbs on all copies of pIII were prepared as described above, except that: (i) smaller volumes (100&#x02009;mL) of 2&#x02009;&#x000D7;&#x02009;YT broth were inoculated with 1&#x02009;mL phagemid-bearing <italic>E. coli</italic> TG1 cells, (ii) phagemid libraries were rescued with M13K07&#x00394;pIII hyper phage at a multiplicity of infection of 10:1, and (iii) the final overnight culture volume was 150&#x02009;mL of 2&#x02009;&#x000D7;&#x02009;YT broth.</p>
<p>For panning, 5&#x02009;&#x000B5;g of either protein A (for the VHB82<sub>SS</sub> library; Thermo-Fisher) or protein L (for the VL383<sub>SS</sub> library; Thermo-Fisher) in 50&#x02009;&#x000B5;L PBS, pH 7.4, was adsorbed overnight at 4&#x000B0;C in wells of NUNC MaxiSorp&#x02122; 96-well microtiter plates. The next day, wells were blocked with 300&#x02009;&#x000B5;L PBS containing either 2% BSA or skim milk for 1&#x02009;h at 37&#x000B0;C, then rinsed 1&#x02009;&#x000D7; with PBS. Approximately 10<sup>11</sup> infective library phage particles (10<sup>12</sup> virions) were added to wells in 100&#x02009;&#x000B5;L of PBS containing 1% skim milk and 0.1% Tween-20 for 2&#x02009;h at room temperature. Wells were washed 5&#x02009;&#x000D7; with PBS containing 0.1% Tween-20, 2&#x02009;&#x000D7; with PBS and then bound phage were eluted for 10&#x02009;min with 50&#x02009;&#x000B5;L of 100&#x02009;mM triethylamine, neutralized with 50&#x02009;&#x000B5;L 1&#x02009;M Tris-HCl, pH 7.5, and used to reinfect exponentially growing <italic>E. coli</italic> TG1 cells. The cultures were superinfected with either M13K07 helper phage or M13K07&#x00394;pIII hyper phage. The next day, amplified phage were purified by polyethylene glycol precipitation from 10&#x02009;mL overnight cultures and used in subsequent panning rounds. After three rounds of selection, pools of sdAb-phage (either phage bound by and eluted from protein A/L, or phage amplified from overnight cultures) were interrogated using next-generation DNA sequencing (NGS) as described below.</p>
</sec>
<sec id="S2-7">
<title>Soluble V<sub>H</sub>/V<sub>L</sub> Protein Expression</title>
<p>Monomeric V<sub>H</sub>/V<sub>L</sub> sdAbs bearing C-terminal 6&#x02009;&#x000D7;&#x02009;His and c-Myc tags were expressed from overnight cultures of <italic>E. coli</italic> TG1 cells grown in 250&#x02009;mL to 1&#x02009;L of 2&#x02009;&#x000D7;&#x02009;YT broth under IPTG (isopropyl &#x003B2;-<sc>D</sc>-1-thiogalactopyranoside) induction, then extracted from periplasmic space by osmotic sucrose shock and purified by immobilized metal affinity chromatography as previously described (<xref ref-type="bibr" rid="B42">42</xref>). For small-scale expression screening, 5&#x02009;mL overnight cultures were grown as above, lysed using FastBreak&#x02122; reagent (Promega, Madison, WI, USA) and sdAbs purified using PureProteome&#x02122; nickel magnetic beads (EMD Millipore, Billerica, MA, USA). Expression yields from 5&#x02009;mL cultures were determined using the Bradford protein assay (Bio-Rad, Hercules, CA, USA) as per manufacturer&#x02019;s instructions with a V<sub>H</sub>H sdAb of known concentration as the protein standard. Titration ELISAs using soluble V<sub>H</sub>/V<sub>L</sub> sdAbs were performed as previously described (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>), using either anti-6&#x02009;&#x000D7;&#x02009;His or anti-c-Myc secondary antibodies to detect binding.</p>
</sec>
<sec id="S2-8">
<title>Size Exclusion Chromatography (SEC) and SEC with Multiangle Light Scattering (MALS)</title>
<p>Size exclusion chromatography analyses of monomeric V<sub>H</sub>/V<sub>L</sub> sdAbs were conducted using a Superdex&#x02122; 75&#x02009;GL column (GE Healthcare) connected to an &#x000C4;KTA FPLC protein purification system (GE Healthcare) as previously described (<xref ref-type="bibr" rid="B42">42</xref>). UPLC-SEC-MALS analyses of V<sub>H</sub>/V<sub>L</sub> sdAbs were conducted essentially as previously described (<xref ref-type="bibr" rid="B39">39</xref>) using an Acquity BEH-125 column (Waters, Milford, MA) connected to an Acquity UPLC H-Class Bio system (Waters) with miniDAWN&#x02122; MALS detector and Optilab<sup>&#x000AE;</sup> UT-rEX&#x02122; refractometer (Wyatt Technology, Santa Barbara, CA, USA). V<sub>H</sub>/V<sub>L</sub> sdAbs (10&#x02013;20&#x02009;&#x000B5;g) were injected at 30&#x000B0;C in a mobile phase consisting of calcium- and magnesium-free DPBS (GE Healthcare) at a flow rate of 0.4&#x02009;mL/min. Weighted average molecular mass (<italic>M</italic><sub>MALS</sub>) was calculated using a protein concentration determined using A<sub>280</sub> from the PDA detector with extinction coefficients calculated from amino acid sequences. Data were processed using ASTRA 6.1 software (Wyatt).</p>
</sec>
<sec id="S2-9">
<title>Surface Plasmon Resonance (SPR)</title>
<p>All monomeric human V<sub>H</sub>/V<sub>L</sub> sdAbs were SEC-purified and buffer-exchanged into HBS-EP buffer (10&#x02009;mM HEPES, 150&#x02009;mM NaCl, 3&#x02009;mM EDTA, 0.005% (v/v) surfactant P20, pH 7.4) prior to SPR analyses. All SPR analyses were performed on a Biacore&#x02122; 3000 instrument (GE Healthcare) at a temperature of 25&#x000B0;C. Briefly, proteins (CEACAM6, 370 resonance units (RUs); HSA, 1614 RUs; GITR, 796 RUs; MBP-intimin, 1536 RUs) were immobilized <italic>via</italic> amine coupling on research-grade CM5 sensor chips (GE Healthcare) in 10&#x02009;mM acetate buffer, pH 4.0, according to the manufacturer&#x02019;s instructions. V<sub>H</sub>/V<sub>L</sub> sdAbs were injected at concentrations ranging from 1&#x02009;nM to 10&#x02009;&#x000B5;M, at flow rates of 20&#x02013;50&#x02009;&#x000B5;L/min and with contact time between 120&#x02009;s and 300&#x02009;s, then allowed to dissociate for 7&#x02013;10&#x02009;min. All surfaces were regenerated using 10&#x02009;mM glycine, pH 1.5. Ethanolamine-blocked flow cells served as reference surfaces. The data were fitted to a 1:1 interaction model and binding affinities (<italic>K</italic><sub>D</sub>s) and/or kinetic parameters were determined either by steady-state analysis or by multicycle kinetic analysis using BIAevaluation 4.1 software (GE Healthcare).</p>
<p>Surface plasmon resonance analyses of two V<sub>L</sub> sdAbs (VL<sub>SS</sub>-2 and VL<sub>SS</sub>-5) against MBP-intimin were conducted as described above, except that 234 RUs of MBP-intimin were immobilized on a research-grade C1 sensor chip (GE Healthcare) <italic>via</italic> amine coupling in 10&#x02009;mM acetate buffer, pH 4.5, according to the manufacturer&#x02019;s instructions. These two V<sub>L</sub> sdAbs were injected in HBS-EP buffer containing either 150 or 500&#x02009;mM NaCl with an extended contact time (600&#x02009;s).</p>
</sec>
<sec id="S2-10">
<title>Protein Turbidity Assays</title>
<p>V<sub>H</sub>/V<sub>L</sub> sdAb samples (0.2&#x02009;mL) in 1.5&#x02009;mL microcentrifuge tubes were heated to 85&#x000B0;C in a heating block for 10&#x02009;min, then allowed to cool to room temperature for 30&#x02009;min. Absorbance at 360&#x02009;nm was measured pre- and post-heat treatment in a quartz NanoQuant Plate&#x02122; (Tecan, M&#x000E4;nnedorf, Switzerland) using an Infinite<sup>&#x000AE;</sup> M200 PRO microplate reader (Tecan). V<sub>H</sub>/V<sub>L</sub> sdAb concentrations were adjusted to 0.25&#x02009;mg/mL in PBS prior to analysis.</p>
</sec>
<sec id="S2-11">
<title>Thermal Shift Assays</title>
<p>V<sub>H</sub>/V<sub>L</sub> sdAb samples (45&#x02009;&#x000B5;L) in 96-well thin-wall optical plates (Bio-Rad) were mixed with 5&#x02009;&#x000B5;L SYPRO<sup>&#x000AE;</sup> Orange (diluted 1:100 from 5,000&#x02009;&#x000D7;&#x02009;stock; Life Technologies, Carlsbad, CA, USA) and sealed with optical quality sealing tape (Bio-Rad). Using an iQ&#x02122; 5 real-time PCR system (Bio-Rad), a temperature ramp of 1&#x000B0;C/min was applied and thermal unfolding was monitored by measuring fluorescence at 0.5&#x000B0;C intervals as previously described (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B47">47</xref>). The wavelengths for excitation and emission were 490 and 575&#x02009;nm, respectively. Melting temperatures (<italic>T</italic><sub>m</sub>s) were calculated as the temperature at which the maximum rate of change in fluorescent signal (d(RFU)/d<italic>t</italic>) was achieved. V<sub>H</sub>/V<sub>L</sub> sdAb concentrations were adjusted to 1&#x02009;mg/mL in PBS prior to analysis.</p>
</sec>
<sec id="S2-12">
<title>Circular Dichroism</title>
<p><italic>T</italic><sub>m</sub>s were also determined by circular dichroism as previously described (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B40">40</xref>). Ellipticity of V<sub>H</sub>/V<sub>L</sub> sdAbs (100&#x02009;&#x000B5;g/mL) was measured at wavelengths between 205 and 210&#x02009;nm in 100&#x02009;mM sodium phosphate buffer, pH 7.4. Ellipticity measurements were normalized to a percentage scale and then <italic>T</italic><sub>m</sub>s were determined by plotting percent folded versus temperature and fitting the data to a Boltzmann distribution.</p>
</sec>
<sec id="S2-13">
<title>Next-Generation DNA Sequencing</title>
<p>V<sub>H</sub>/V<sub>L</sub> sdAb libraries were interrogated using an Illumina MiSeq instrument as described previously (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B48">48</xref>). Amplicons for NGS were prepared using FR1- and FR4-specific barcoded primers (sequences in Table S1 in Supplementary Material) using as template either phagemid DNA (&#x0007E;10&#x02009;ng) or phage virions (&#x0007E;10<sup>6</sup> particles).</p>
</sec>
<sec id="S2-14">
<title>Statistical Analyses</title>
<p>Descriptive statistics (mean, median) were used to describe datasets as described in figure legends. No inferential statistical tests were used.</p>
</sec>
</sec>
<sec id="S3">
<title>Results</title>
<p>Antigen-specific human autonomous V<sub>H</sub>/V<sub>L</sub> sdAbs do not exist in nature, and are most commonly isolated from synthetically randomized <italic>in vitro</italic> display libraries. These molecules are notoriously unstable and aggregation prone (<xref ref-type="bibr" rid="B4">4</xref>), which probably negatively impacts the selection of antigen-specific binders from synthetic V<sub>H</sub>/V<sub>L</sub> sdAb libraries. In an effort to mitigate these factors, we attempted to identify ultra-stable V<sub>H</sub>/V<sub>L</sub> sdAb scaffolds upon which we could construct highly diverse, stability-enhanced phage-displayed V<sub>H</sub>/V<sub>L</sub> sdAb libraries designed to yield soluble and thermostable antigen-specific human sdAbs.</p>
<sec id="S3-1">
<title>Biophysical Stability Assessment of Wild-Type Human V<sub>H</sub>/V<sub>L</sub> sdAb Scaffolds</title>
<p>The <italic>T</italic><sub>m</sub>s and aggregation tendencies of 22 potential V<sub>H</sub> sdAb scaffolds and 18 potential V<sub>L</sub> sdAb scaffolds were determined by circular dichroism and SEC (Tables S2 and S3 in Supplementary Material). Five V<sub>H</sub> and five V<sub>L</sub> sdAb scaffolds as well as their disulfide-stabilized equivalents (Table <xref ref-type="table" rid="T1">1</xref>) were selected as the most promising candidates for library construction based on: (i) primarily monomeric folding, (ii) high thermostability with reversible thermal unfolding, and (iii) reasonable expression yields (&#x0003E;1&#x02009;mg/L) from overnight <italic>E. coli</italic> TG1 cultures. As reported previously (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B40">40</xref>), incorporation of a disulfide linkage spanning IMGT positions 54&#x02013;78 increased the <italic>T</italic><sub>m</sub> of each scaffold by &#x0007E;5&#x02013;20&#x000B0;C but also had unpredictable effects on expression yields.</p>
</sec>
<sec id="S3-2">
<title>Tolerance of Human V<sub>H</sub>/V<sub>L</sub> sdAb Scaffolds to CDR Modification</title>
<p>As a preliminary investigation into which of the 20 V<sub>H</sub>/V<sub>L</sub> sdAb scaffolds might best tolerate library randomization, we grafted 12 sets of exogenous CDRs (Table <xref ref-type="table" rid="T2">2</xref>) into each scaffold and assessed the resulting molecules&#x02019; expression level (Bradford assay), aggregation tendency (SEC-MALS), <italic>T</italic><sub>m</sub> (thermal shift assay), and ability to refold after thermal denaturation (turbidity assay). For V<sub>L</sub> sdAb scaffolds, the 12 sets of exogenous CDRs were derived from non-antigen-specific human V<sub>L</sub> sdAbs isolated from previously constructed libraries with expression yields &#x02265;10&#x02009;mg/L and for V<sub>H</sub> sdAb scaffolds, the 12 sets of exogenous CDRs were selected from either human V<sub>H</sub> sdAbs of unknown antigen specificity isolated from previously constructed libraries or camelid V<sub>H</sub>H sdAbs with expression yields &#x02265;3&#x02009;mg/L.</p>
<p>The V<sub>L</sub> sdAb scaffolds yielding the best-expressing CDR-shuffled variants were VL383<sub>SS</sub>, VL325<sub>SS</sub> and VL335<sub>SS</sub> (Figure <xref ref-type="fig" rid="F1">1</xref>A). CDR-shuffled variants of VL383<sub>SS</sub> and VL325<sub>SS</sub> were primarily monomeric by SEC-MALS, while CDR-shuffled variants of VL335<sub>SS</sub> showed some tendency to aggregate (Figure <xref ref-type="fig" rid="F1">1</xref>C). All three of these V<sub>L</sub> sdAb scaffolds, especially VL325<sub>SS</sub>, yielded CDR-shuffled variants with high <italic>T<sub>m</sub></italic>s (Figure <xref ref-type="fig" rid="F1">1</xref>E); however, many CDR-shuffled variants of VL325<sub>SS</sub> showed significant turbidity upon heat denaturation (Figure <xref ref-type="fig" rid="F1">1</xref>G), reflecting their inability to refold as soluble monomers. The V<sub>H</sub> sdAb scaffolds yielding the best-expressing CDR-shuffled variants were VH420, VH428, VHB82, VHB82<sub>SS</sub>, and VHM81<sub>SS</sub> (Figure <xref ref-type="fig" rid="F1">1</xref>B). CDR-shuffled variants of all five of these V<sub>H</sub> sdAb scaffolds were similarly monomeric (Figure <xref ref-type="fig" rid="F1">1</xref>D) but as expected, the two disulfide-stabilized sdAb scaffolds (VHB82<sub>SS</sub> and VHM81<sub>SS</sub>) yielded CDR-shuffled variants with higher <italic>T<sub>m</sub></italic>s (Figure <xref ref-type="fig" rid="F1">1</xref>F). Similar proportions of the CDR-shuffled variants of all five V<sub>H</sub> sdAb scaffolds showed minor turbidity upon heat denaturation (Figure <xref ref-type="fig" rid="F1">1</xref>H). On the basis of these data, we selected one V<sub>L</sub> sdAb scaffold (VL383<sub>SS</sub>) and two V<sub>H</sub> sdAb scaffolds (VH428 and VHB82<sub>SS</sub>) for library construction, reflecting a balance of their tolerance to CDR modification as well as their differing CDR3 lengths and germline gene rearrangements.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>Biophysical stability assessment of complementarity-determining region (CDR)-shuffled human V<sub>H</sub>/V<sub>L</sub> single-domain antibody (sdAb) variants. <bold>(A,B)</bold> Expression yields of CDR-shuffled V<sub>L</sub> <bold>(A)</bold> and V<sub>H</sub> <bold>(B)</bold> sdAbs from 5&#x02009;mL overnight cultures, as determined by Bradford assay. Two outliers (VL382&#x02009;&#x0002B;&#x02009;CDR set 9, expression yield 467.7&#x02009;&#x000B5;g/mL and VH428<sub>SS</sub>&#x02009;&#x0002B;&#x02009;CDR set 2, 356.4&#x02009;&#x000B5;g/mL) are indicated by green triangles. <bold>(C,D)</bold> Aggregation tendencies of CDR-shuffled V<sub>L</sub> <bold>(C)</bold> and V<sub>H</sub> <bold>(D)</bold> sdAbs, as determined by SEC-MALS. <bold>(E,F)</bold> Melting temperatures (<italic>T<sub>m</sub></italic>s) of CDR-shuffled V<sub>L</sub> <bold>(E)</bold> and V<sub>H</sub> <bold>(F)</bold> sdAbs, as determined by thermal shift assay. <bold>(G,H)</bold> Turbidity upon thermal denaturation of CDR-shuffled V<sub>L</sub> <bold>(G)</bold> and V<sub>H</sub> <bold>(H)</bold> sdAbs, as measured by spectrophotometry at 360&#x02009;nm wavelength. Dashed lines represent the range of turbidity measurements for unheated V<sub>H</sub>/V<sub>L</sub> sdAbs. The aggregation tendencies, <italic>T<sub>m</sub></italic>s and turbidities of CDR-shuffled variants of VH429 were not characterized due to inadequate expression yields. Horizontal lines represent mean <bold>(C,D,G,H)</bold> or median <bold>(A,B,E,F)</bold> values and wild-type V<sub>H</sub>/V<sub>L</sub> sdAbs with unmodified CDRs are shown in red. Open and solid circles represent V<sub>H</sub>/V<sub>L</sub> sdAbs with, or without, a stabilizing exogenous disulfide linkage. The number of data points in each panel reflects whether the experiment was conducted in singlicate <bold>(C,E)</bold> or duplicate <bold>(A,B,D,F&#x02013;H)</bold> and for panels <bold>(C&#x02013;H)</bold>, whether the CDR-shuffled variant expressed sufficiently for analysis.</p></caption>
<graphic xlink:href="fimmu-08-01759-g001.tif"/>
</fig>
</sec>
<sec id="S3-3">
<title>Design and Construction of Phage-Displayed Human V<sub>H</sub>/V<sub>L</sub> sdAb Libraries</title>
<p>Three synthetic sdAb libraries (VL383<sub>SS</sub>, VH428, and VHB82<sub>SS</sub>) were constructed by limited <italic>in vitro</italic> randomization of the CDRs of these V<sub>H</sub>/V<sub>L</sub> sdAb scaffolds and cloning of the resulting DNA into the pMED1 phagemid vector (Figures <xref ref-type="fig" rid="F2">2</xref>A,B). CDR3 length was varied in each library (Figures <xref ref-type="fig" rid="F2">2</xref>A,D; VL383<sub>SS</sub> library: 8, 9, or 10 residues; VH428 and VHB82<sub>SS</sub> libraries: 10, 12, 14, 16, 18, 20, or 22 residues) while CDR1 and CDR2 lengths were constant. The major technical advances of these over our previously described phage-displayed synthetic human V<sub>H</sub>/V<sub>L</sub> sdAb libraries (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B31">31</xref>) were (i) trinucleotide mutagenesis allowed for incorporation of defined mixtures of amino acids at each randomization position, based on alignments of human and llama antibodies with additional bias toward solubility-promoting residues (Asp, Glu) and against undesirable residues (Asn, Cys, and Met) and stop codons (Figures <xref ref-type="fig" rid="F2">2</xref>B,C; Figure S2 in Supplementary Material) and (ii) near-complete randomization of all three CDRs of each V<sub>H</sub>/V<sub>L</sub> sdAb scaffold resulted in much higher sequence diversity for the vast majority of library molecules (Figure <xref ref-type="fig" rid="F2">2</xref>E). All three V<sub>H</sub>/V<sub>L</sub> sdAb libraries were transformed into <italic>E. coli</italic> TG1 cells, yielding final library sizes (1.0&#x02013;2.3&#x02009;&#x000D7;&#x02009;10<sup>10</sup> independent transformants) that, as expected, vastly under-sampled theoretical library diversity (VL383<sub>SS</sub>: 2.9&#x02009;&#x000D7;&#x02009;10<sup>13</sup> unique sequences; VHB82<sub>SS</sub>: 2.3&#x02009;&#x000D7;&#x02009;10<sup>33</sup> unique sequences; VH428: 2.3&#x02009;&#x000D7;&#x02009;10<sup>35</sup> unique sequences). At this stage, prior to helper phage rescue, no major clonality biases or deviations from library design were observed (data not shown).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>Design and construction of the VL383<sub>SS</sub>, VH428, and VHB82<sub>SS</sub> synthetic human V<sub>H</sub>/V<sub>L</sub> single-domain antibody (sdAb) libraries. <bold>(A)</bold> Design of the human V<sub>H</sub>/V<sub>L</sub> sdAb libraries. The parental V<sub>H</sub>/V<sub>L</sub> sdAb sequence is shown at top with IMGT numbering. Intradomain disulfide linkage-forming cysteine residues at positions 54 and 78 are shown in magenta. Randomization positions are highlighted in either red (no length polymorphism) or green (length polymorphism). Arabic numerals indicate the codon mixture (X1, X2, X3, X4, or X5) incorporated at each randomization position. <bold>(B)</bold> Expected amino acid frequencies at V<sub>H</sub>/V<sub>L</sub> sdAb library randomization positions. <bold>(C)</bold> Observed amino acid frequencies at V<sub>H</sub>/V<sub>L</sub> sdAb library randomization positions, measured from phagemid DNA isolated from <italic>Escherichia coli</italic> TG1 cells. Crossed-out cells indicate a frequency of &#x0003C;0.1%. <bold>(D)</bold> CDR3 length distributions of the V<sub>H</sub>/V<sub>L</sub> sdAb libraries. <bold>(E)</bold> Degree of randomized sequence diversity (Levenshtein distance, or number of amino acid changes with respect to the parental scaffold) in the V<sub>H</sub>/V<sub>L</sub> sdAb libraries. Analyses shown in <bold>(C&#x02013;E)</bold> are representative of 7.7&#x02009;&#x000D7;&#x02009;10<sup>4</sup> to 7.9&#x02009;&#x000D7;&#x02009;10<sup>5</sup> sequences per library.</p></caption>
<graphic xlink:href="fimmu-08-01759-g002.tif"/>
</fig>
</sec>
<sec id="S3-4">
<title>Isolation and Characterization of Antigen-Specific Human V<sub>H</sub>/V<sub>L</sub> sdAbs</title>
<p>All three V<sub>H</sub>/V<sub>L</sub> sdAb libraries were rescued with M13K07 helper phage and panned for four or five rounds against five model antigens (CEACAM6, CTLA4, GITR, HSA, and MBP-intimin). All library pannings were performed in duplicate by two independent operators at the same time and using the same materials, except for panning against MBP-intimin, in which panning was done in triplicate. High attrition rates of V<sub>H</sub>/V<sub>L</sub> sdAbs showing false positive binding either as sdAb-phage or as soluble sdAb proteins (VL383<sub>SS</sub>: 53% attrition; VH428: 69% attrition; VHB82ss: 71% attrition; Table <xref ref-type="table" rid="T3">3</xref>) resulted in a final yield of 20 unique antigen-specific V<sub>H</sub>/V<sub>L</sub> sdAbs against four targets. Of the 15 library-target screens we conducted, eight (53%) yielded at least one antigen-specific V<sub>H</sub>/V<sub>L</sub> sdAb (four screens yielded one sdAb, two screens yielded two sdAbs, one screen yielded three sdAbs, and two screens yielded five sdAbs). Most of the recovered sdAbs were monomeric (Figure <xref ref-type="fig" rid="F3">3</xref>A; Table <xref ref-type="table" rid="T4">4</xref>; Figure S3 in Supplementary Material), thermostable (Figure <xref ref-type="fig" rid="F3">3</xref>B; Table <xref ref-type="table" rid="T4">4</xref>), and had affinities for antigen ranging from 5&#x02009;nM to &#x0007E;12&#x02009;&#x003BC;M (Figures <xref ref-type="fig" rid="F3">3</xref>C,D; Table <xref ref-type="table" rid="T4">4</xref>). One notable exception was the &#x003B1;-GITR V<sub>H</sub> sdAb VHB82<sub>SS</sub>-6, whose elution volume by SEC suggested it existed in solution as a strict dimer (Figure <xref ref-type="fig" rid="F3">3</xref>A). Stable homodimerization has previously been reported for several human V<sub>H</sub> sdAbs and was critical for antigen binding (<xref ref-type="bibr" rid="B49">49</xref>&#x02013;<xref ref-type="bibr" rid="B52">52</xref>); this phenomenon is distinct from the general tendency of some V<sub>H</sub> domains to forms soluble aggregates. Antigen-specific V<sub>H</sub>/V<sub>L</sub> sdAbs isolated from all three libraries had aggregation tendencies and thermostabilities reflective of the parental V<sub>H</sub>/V<sub>L</sub> sdAb scaffold from which they were derived, but generally poorer expression yields (Figure <xref ref-type="fig" rid="F4">4</xref>A). Reproducibility in the selection of specific sdAb sequences from the libraries was modest, with only 45% (9/20) of antigen-specific V<sub>H</sub>/V<sub>L</sub> sdAbs recovered by both operators (Figure <xref ref-type="fig" rid="F4">4</xref>B) and no apparent connection between antigen-binding affinity and consistency of isolation.</p>
<table-wrap position="float" id="T3">
<label>Table 3</label>
<caption><p>Attrition rates of human V<sub>H</sub>/V<sub>L</sub> single-domain antibodies (sdAbs) through isolation and characterization.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left" rowspan="2">Library</th>
<th valign="top" align="left" rowspan="2">Target</th>
<th valign="top" align="center" colspan="3">No. of binding sdAbs<hr/></th>
</tr><tr>
<th valign="top" align="center">Phage ELISA</th>
<th valign="top" align="center">Soluble ELISA</th>
<th valign="top" align="center">SPR</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="5">VL383<sub>SS</sub></td>
<td align="left" valign="top">CEACAM6</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top">CTLA4</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">GITR</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top"/>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">HSA</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">MBP-intimin<xref ref-type="table-fn" rid="tfn9"><sup>a</sup></xref></td>
<td align="center" valign="top">3, 5</td>
<td align="center" valign="top">2, 4</td>
<td align="center" valign="top">2, 4</td>
</tr>
<tr>
<td align="left" valign="top" colspan="2"/>
<td align="center" valign="top">15 (100%)</td>
<td align="center" valign="top">7 (47%)</td>
<td align="center" valign="top">7 (47%)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="5">VH428</td>
<td align="left" valign="top">CEACAM6</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">3</td>
</tr>
<tr>
<td align="left" valign="top">CTLA4</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">GITR</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">HSA</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">MBP-intimin</td>
<td align="center" valign="top">4</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">2</td>
</tr>
<tr>
<td align="left" valign="top" colspan="2"/>
<td align="center" valign="top">16 (100%)</td>
<td align="center" valign="top">5 (31%)</td>
<td align="center" valign="top">5 (31%)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="5">VHB82<sub>SS</sub></td>
<td align="left" valign="top">CEACAM6</td>
<td align="center" valign="top">5</td>
<td align="center" valign="top">5</td>
<td align="center" valign="top">5</td>
</tr>
<tr>
<td align="left" valign="top">CTLA4</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">GITR</td>
<td align="center" valign="top">5</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top">HSA</td>
<td align="center" valign="top">6</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top">MBP-intimin</td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">1</td>
</tr>
<tr>
<td align="left" valign="top" colspan="2"/>
<td align="center" valign="top">28 (100%)</td>
<td align="center" valign="top">11 (39%)</td>
<td align="center" valign="top">8 (29%)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="5"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" colspan="2">Total</td>
<td align="center" valign="top">59 (100%)</td>
<td align="center" valign="top">23 (39%)</td>
<td align="center" valign="top">20 (34%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn9"><p><italic><sup>a</sup>Double entries reflect two independent isolation attempts</italic>.</p></fn></table-wrap-foot></table-wrap>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>Properties of selected antigen-specific single-domain antibodies (sdAbs) isolated from the VL383<sub>SS</sub>, VH428, and VHB82<sub>SS</sub> synthetic human V<sub>H</sub>/V<sub>L</sub> sdAb libraries. The single highest affinity sdAb against each target is shown, except for MBP-intimin, where VL<sub>SS</sub>-3 is shown instead of VL<sub>SS</sub>-4 or VL<sub>SS</sub>-5 because of better fit to a 1:1 binding model. <bold>(A)</bold> Size exclusion chromatography (SEC) profiles of representative antigen-specific human V<sub>H</sub>/V<sub>L</sub> sdAbs. Arrows show molecular mass standards, from left to right: thyroglobulin (670&#x02009;kDa), gamma globulin (158&#x02009;kDa), ovalbumin (44&#x02009;kDa), myoglobin (17&#x02009;kDa), and vitamin B12 (1.35&#x02009;kDa). <bold>(B)</bold> Thermal unfolding of representative antigen-specific V<sub>H</sub>/V<sub>L</sub> sdAbs as determined by circular dichroism. Replicate unfolding curves are shown in red and blue; the sdAbs were then cooled to room temperature and remelted (shown in orange and green). <bold>(C)</bold> Titration ELISA of representative antigen-specific V<sub>H</sub>/V<sub>L</sub> sdAbs. Horseradish peroxidase mouse anti-c-Myc secondary antibody (clone 9E10, diluted 1:3,000) was used for detection. <bold>(D)</bold> Binding of antigen-specific V<sub>H</sub>/V<sub>L</sub> sdAbs to cognate antigen by SPR. Each antigen was immobilized on a CM5 sensor chip using amine coupling, then the indicated V<sub>H</sub> or V<sub>L</sub> sdAb was flowed over the surface at concentrations ranging from 25 to 1,000&#x02009;nM (&#x003B1;-CEACAM6 VHB82<sub>SS</sub>-2), 25 to 500&#x02009;nM (&#x003B1;-GITR VHB82<sub>SS</sub>-6), 2.5 to 50&#x02009;nM (&#x003B1;-HSA VHB82<sub>SS</sub>-7), or 62.5 to 2,500&#x02009;nM (&#x003B1;-MBP-intimin VL383<sub>SS</sub>-3). Black lines show data and red lines show fits.</p></caption>
<graphic xlink:href="fimmu-08-01759-g003.tif"/>
</fig>
<table-wrap position="float" id="T4">
<label>Table 4</label>
<caption><p>Properties of antigen-specific single-domain antibodies (sdAbs) isolated from the phage-displayed synthetic human V<sub>H</sub>/V<sub>L</sub> libraries.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Target</th>
<th valign="top" align="left">V<sub>H</sub>/V<sub>L</sub> sdAb</th>
<th valign="top" align="center">Expression yield (mg/L)</th>
<th valign="top" align="center">Monomer (%)</th>
<th valign="top" align="center"><italic>T</italic><sub>m</sub> (&#x000B0;C)</th>
<th valign="top" align="center"><italic>K</italic><sub>D</sub> (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="9">CEACAM6</td>
<td align="left" valign="top">VL383<sub>SS</sub>-1</td>
<td align="center" valign="top">18.4</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">76.9</td>
<td align="center" valign="top">454<xref ref-type="table-fn" rid="tfn10"><sup>a</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">VH428-1</td>
<td align="center" valign="top">3.4</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">57.6</td>
<td align="center" valign="top">2,180<xref ref-type="table-fn" rid="tfn10"><sup>a</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">VH428-2</td>
<td align="center" valign="top">3.6</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">61.5</td>
<td align="center" valign="top">1,230<xref ref-type="table-fn" rid="tfn11"><sup>b</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">VH428-3</td>
<td align="center" valign="top">1.9</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">52.9</td>
<td align="center" valign="top">290<xref ref-type="table-fn" rid="tfn11"><sup>b</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">VHB82<sub>SS</sub>-1</td>
<td align="center" valign="top">6.4</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">81.4</td>
<td align="center" valign="top">638<xref ref-type="table-fn" rid="tfn11"><sup>b</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">VHB82<sub>SS</sub>-2</td>
<td align="center" valign="top">18.8</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">75.1</td>
<td align="center" valign="top">245<xref ref-type="table-fn" rid="tfn11"><sup>b</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">VHB82<sub>SS</sub>-3</td>
<td align="center" valign="top">5.4</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">72.5</td>
<td align="center" valign="top">2,730<xref ref-type="table-fn" rid="tfn10"><sup>a</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">VHB82<sub>SS</sub>-4</td>
<td align="center" valign="top">3.2</td>
<td align="center" valign="top">80.0</td>
<td align="center" valign="top">68.3</td>
<td align="center" valign="top">1,070<xref ref-type="table-fn" rid="tfn10"><sup>a</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">VHB82<sub>SS</sub>-5</td>
<td align="center" valign="top">2.4</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">71.9</td>
<td align="center" valign="top">2,200<xref ref-type="table-fn" rid="tfn10"><sup>a</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">GITR</td>
<td align="left" valign="top">VHB82<sub>SS</sub>-6</td>
<td align="center" valign="top">7.2</td>
<td align="center" valign="top">0<xref ref-type="table-fn" rid="tfn14"><sup>e</sup></xref></td>
<td align="center" valign="top">81.4</td>
<td align="center" valign="top">196<xref ref-type="table-fn" rid="tfn11"><sup>b</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">HSA</td>
<td align="left" valign="top">VHB82<sub>SS</sub>-7</td>
<td align="center" valign="top">8.0</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">67.7</td>
<td align="center" valign="top">5<xref ref-type="table-fn" rid="tfn11"><sup>b</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="9">MBP-intimin</td>
<td align="left" valign="top">VL383<sub>SS</sub>-2</td>
<td align="center" valign="top">2.0</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">69.6</td>
<td align="center" valign="top">905<sup>b,c</sup></td>
</tr>
<tr>
<td align="left" valign="top">VL383<sub>SS</sub>-3</td>
<td align="center" valign="top">0.2</td>
<td align="center" valign="top">83.4</td>
<td align="center" valign="top">65.1</td>
<td align="center" valign="top">395<xref ref-type="table-fn" rid="tfn11"><sup>b</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">VL383<sub>SS</sub>-4</td>
<td align="center" valign="top">1.2</td>
<td align="center" valign="top">88.7</td>
<td align="center" valign="top">65.3</td>
<td align="center" valign="top">227<xref ref-type="table-fn" rid="tfn11"><sup>b</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">VL383<sub>SS</sub>-5</td>
<td align="center" valign="top">3.7</td>
<td align="center" valign="top">94.6</td>
<td align="center" valign="top">74.2</td>
<td align="center" valign="top">252<sup>b,c</sup></td>
</tr>
<tr>
<td align="left" valign="top">VL383<sub>SS</sub>-6</td>
<td align="center" valign="top">9.9</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">76.6</td>
<td align="center" valign="top">7,470<xref ref-type="table-fn" rid="tfn10"><sup>a</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">VL383<sub>SS</sub>-7</td>
<td align="center" valign="top">8.0</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">76.7</td>
<td align="center" valign="top">11,500<sup>a,d</sup></td>
</tr>
<tr>
<td align="left" valign="top">VH428-4</td>
<td align="center" valign="top">0.1</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">58.9</td>
<td align="center" valign="top">2,590<xref ref-type="table-fn" rid="tfn11"><sup>b</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">VH428-5</td>
<td align="center" valign="top">0.1</td>
<td align="center" valign="top">&#x0003E;95</td>
<td align="center" valign="top">n.d.</td>
<td align="center" valign="top">4,430<xref ref-type="table-fn" rid="tfn10"><sup>a</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">VHB82<sub>SS</sub>-8</td>
<td align="center" valign="top">8.0</td>
<td align="center" valign="top">72.5</td>
<td align="center" valign="top">69.3</td>
<td align="center" valign="top">5,230<xref ref-type="table-fn" rid="tfn10"><sup>a</sup></xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn10"><p><italic><sup>a</sup>Determined using steady-state analysis at 25&#x000B0;C</italic>.</p></fn>
<fn id="tfn11"><p><italic><sup>b</sup>Determined using multicycle kinetic analysis and fitting to a 1:1 binding model at 25&#x000B0;C</italic>.</p></fn>
<fn id="tfn12"><p><italic><sup>c</sup>Antigen was immobilized on a C1 sensor chip, evidence of complex binding</italic>.</p></fn>
<fn id="tfn13"><p><italic><sup>d</sup>K<sub>D</sub> is an estimate only due to lack of curvature in the steady-state plot</italic>.</p></fn>
<fn id="tfn14"><p><italic><sup>e</sup>Size exclusion chromatography elution volume suggests VHB82<sub>SS</sub>-6 is a strict dimer</italic>.</p></fn><p><italic>n.d., not determined</italic>.</p></table-wrap-foot></table-wrap>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption><p>Properties of all antigen-specific single-domain antibodies (sdAbs) isolated from the VL383<sub>SS</sub>, VH428 and VHB82<sub>SS</sub> synthetic human V<sub>H</sub>/V<sub>L</sub> sdAb libraries. <bold>(A)</bold> Expression yields (as measured by spectrophotometry at 280&#x02009;nm), <italic>T<sub>m</sub></italic>s (as determined by circular dichroism), and aggregation tendencies (as determined by size exclusion chromatography) of antigen-specific V<sub>H</sub>/V<sub>L</sub> sdAbs isolated from the libraries in comparison to the parental scaffold from which they were derived (shown in red). <bold>(B)</bold> Interoperator reproducibility in isolating individual V<sub>H</sub>/V<sub>L</sub> sdAb sequences.</p></caption>
<graphic xlink:href="fimmu-08-01759-g004.tif"/>
</fig>
</sec>
<sec id="S3-5">
<title>Evaluation of Stability-Sequence Diversity Tradeoffs in Human V<sub>H</sub>/V<sub>L</sub> sdAb Libraries</title>
<p>To better understand potential constraints on the CDR sequences of monomeric and stable human V<sub>H</sub>/V<sub>L</sub> sdAbs, we examined the effects of stability selection (three rounds of protein A or L selection followed by amplification of the eluted phage overnight in <italic>E. coli</italic> TG1 cells; Figure <xref ref-type="fig" rid="F5">5</xref>) on randomized sequence diversity of two V<sub>H</sub>/V<sub>L</sub> sdAb libraries (VL383<sub>SS</sub> and VHB82<sub>SS</sub>). We performed this experiment in duplicate using either phage particles displaying monovalent sdAb (rescued with M13K07 helper phage; simultaneous expression of pIII from helper phage and pIII-sdAb from phagemid) or phage particles displaying multivalent sdAb (rescued with M13K07&#x00394;pIII hyper phage; only pIII-sdAb expressed from phagemid). Out-of-frame and/or stop-codon-encoding V<sub>H</sub>/V<sub>L</sub> sdAb clones were rare in both libraries (&#x0201C;Library Cells&#x0201D;), but rose substantially in frequency upon phage rescue (&#x0201C;Library Phage&#x0201D;) and upon amplification in <italic>E. coli</italic> (&#x0201C;Amplification in <italic>E. coli</italic>&#x0201D;), suggesting a growth advantage for non-sdAb expressing cells over sdAb-expressing ones (Figures <xref ref-type="fig" rid="F5">5</xref>A,B); this phenomenon was mitigated somewhat using hyper phage rescue. After three rounds of protein A/L selection and overnight amplification in <italic>E. coli</italic> with helper phage rescue, there were clear clonal biases observed in the resulting populations of sdAb-phage (Figures <xref ref-type="fig" rid="F5">5</xref>C,D). Using an arbitrary frequency cutoff (0.00006% for VL383<sub>SS</sub> and 0.00004% for VHB82<sub>SS</sub>; sdAbs at frequencies greater than these cutoffs were not present in any other dataset) to identify unique sdAb sequences enriched by stability selection, we found that different sdAb clones were selected in the two replicate pannings, although both sets of sdAbs were heavily biased toward the parental V<sub>H</sub>/V<sub>L</sub> sdAb scaffold&#x02019;s CDR3 length (9 residues for the VL383<sub>SS</sub> library and 10 residues for the VHB82<sub>SS</sub> library, which is the shortest CDR3 length possible in the library design and the nearest to the VHB82<sub>SS</sub> scaffold&#x02019;s CDR3 length of 6 residues; Figure S4 in Supplementary Material). However, stability selection reproducibly yielded V<sub>H</sub>/V<sub>L</sub> sdAbs with biased CDR amino acid composition (Figures <xref ref-type="fig" rid="F5">5</xref>E,F; Figures S5 and S6 in Supplementary Material). In order of magnitude, stability biases in the VL383<sub>SS</sub> library favored Asp, His, Pro, Ser and Thr and disfavored aromatic (Phe, Trp, Tyr) and hydrophobic (Ile, Leu, Val) residues. Similarly, stability biases in the VHB82<sub>SS</sub> library favored Asp, His, Pro, and Gln and disfavored aromatic (Phe, Trp, Tyr) and hydrophobic (Ile, Leu, Val) residues. These biases were especially acute at the C-terminus of CDR1 and N-terminus of CDR2, both of which flank FR2. Identical molecular signatures were observed to a lesser degree in the pools of all sdAb-phage (irrespective of frequency or mono- vs. multivalent display format) subjected to three rounds of stability selection (Figures S7 and S8 in Supplementary Material) as well as in the pools of sdAb-phage after phage rescue and eluted from protein A/L (data not shown), suggesting a common ontogeny.</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption><p>Impact of stability selection on human V<sub>H</sub>/V<sub>L</sub> single-domain antibody (sdAb) library sequence diversity. After transformation of <italic>Escherichia coli</italic> TG1 cells with phagemid DNA, phage were rescued by superinfection of overnight cultures with M13K07 helper phage or M13K07&#x00394;pIII hyper phage. The purified sdAb-displaying phage were bound and eluted from protein A (VHB82<sub>SS</sub> library) or protein L (VL383<sub>SS</sub> library), then amplified by reinfection of <italic>E. coli</italic> TG1 cells. Three rounds of panning were performed, and V<sub>H</sub>/V<sub>L</sub> sdAb sequences were interrogated by NGS at the stage of rescued phage, phage eluted after a single round of protein A/L selection, and phage amplified after the final round of panning. <bold>(A,B)</bold> Proportion of functional sdAb sequences (in-frame ORF, no stop codons) observed in V<sub>L</sub> <bold>(A)</bold> and V<sub>H</sub> <bold>(B)</bold> library phage and panning outputs. <bold>(C,D)</bold> Clonality of V<sub>L</sub> <bold>(C)</bold> and V<sub>H</sub> <bold>(D)</bold> library phage and panning outputs. <bold>(E,F)</bold> Complementarity-determining region (CDR) amino acid composition of enriched V<sub>L</sub> <bold>(E)</bold> and V<sub>H</sub> <bold>(F)</bold> sdAb clones after three rounds of stability selection. Crossed-out cells indicate a frequency of &#x0003C;0.1%. Analyses in <bold>(A&#x02013;F)</bold> are representative of 7.7&#x02009;&#x000D7;&#x02009;10<sup>4</sup> to 7.9&#x02009;&#x000D7;&#x02009;10<sup>5</sup> sequences per sample.</p></caption>
<graphic xlink:href="fimmu-08-01759-g005.tif"/>
</fig>
</sec>
</sec>
<sec id="S4" sec-type="discussion">
<title>Discussion</title>
<p>The starting point for this investigation was the observation that several of our previously described synthetic human V<sub>H</sub>/V<sub>L</sub> sdAb libraries performed unpredictably (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B31">31</xref>), yielding monomeric antigen-specific binders against some targets but not others. Thus, we tested the hypothesis that these issues might be solved by: (i) building libraries on ultrastable V<sub>H</sub>/V<sub>L</sub> sdAb scaffolds that maintain their biophysical properties upon CDR modification and (ii) randomizing the CDRs of the V<sub>H</sub>/V<sub>L</sub> sdAb libraries more extensively using trinucleotide mutagenesis. A few general lessons became apparent during the course of these experiments. First, although V<sub>H</sub>/V<sub>L</sub> sdAb scaffolds clearly vary in their tolerance to CDR modification, no &#x0201C;perfect&#x0201D; scaffold exists (i.e., some CDR-shuffled variants of every scaffold showed poor biophysical properties). Second, the trinucleotide mutagenesis approach used here was dramatically more effective at incorporating randomized sequence diversity in V<sub>H</sub>/V<sub>L</sub> sdAb CDRs compared to the Kunkel mutagenesis (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B31">31</xref>) and splicing by overlap extension PCR mutagenesis approaches using degenerate oligonucleotides (<xref ref-type="bibr" rid="B12">12</xref>) that we have used previously. Third, as we showed previously (<xref ref-type="bibr" rid="B31">31</xref>), incorporating a stabilizing exogenous disulfide linkage spanning IMGT positions 54&#x02013;78 into V<sub>H</sub>/V<sub>L</sub> sdAb libraries is clearly compatible with selection of antigen-specific binders, as 15/20 of the binders shown here bear this linkage. Finally, it is clearly possible, at least under some circumstance, to select monomeric, high-affinity binders from synthetic human V<sub>H</sub>/V<sub>L</sub> sdAbs libraries, as evidenced by the &#x003B1;-HSA VH<sub>SS</sub>-7 sdAb (<italic>K</italic><sub>D</sub>: 5&#x02009;nM) reported here.</p>
<p>However, the more general issues afflicting synthetic human V<sub>H</sub>/V<sub>L</sub> sdAb libraries (high attrition rates due to false positive binding, possibly caused by sdAb aggregation; inconsistency of isolation; variable expression yield and aggregation of isolated sdAbs) were not completely solved by using more stable V<sub>H</sub>/V<sub>L</sub> scaffolds or building more diverse and non-degenerate libraries. The additional randomized sequence diversity we achieved by the use of trinucleotide mutagenesis is almost certainly negligible when compared to the theoretical size of the libraries, and massive undersampling may account at least in part for inconsistent isolation of sdAbs. Other potential solutions to the problem of undersampling include increasing throughput (<xref ref-type="bibr" rid="B53">53</xref>), use of V<sub>H</sub>/V<sub>L</sub> sdAb-transgenic mice (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>) and use of <italic>in vitro</italic> VDJ recombination systems (<xref ref-type="bibr" rid="B56">56</xref>). Nonetheless, modest inter-operator reproducibility in isolating the same binders clearly demonstrates that antigen-specific human V<sub>H</sub>/V<sub>L</sub> sdAbs are not always isolated even when they were present in the library. We currently have no understanding of the factors influencing the number of V<sub>H</sub>/V<sub>L</sub> sdAb binders isolated, their affinities or biophysical properties, nor if these depend on the library, the target antigen quality or composition, or the panning methodology. One possibility, for example, is that the numbers of input library sdAb-phage used here, the target antigen surface size and density, and/or the numbers of eluted phage amplified from each round of selection were inadequate to consistently recover very rare sdAb specificities that may be present in the libraries. These factors could be investigated empirically in future studies.</p>
<p>It is virtually certain that some of the challenges of human synthetic V<sub>H</sub>/V<sub>L</sub> sdAbs relate to fundamental tradeoffs between stability and sequence diversity. There is no necessary reason why rare autonomous rearranged human V<sub>H</sub>/V<sub>L</sub> sdAbs should be compatible with any CDR sequence; rather, it should be expected that these molecules rely chiefly on particular CDR sequences for their solubility and stability, given that human V<sub>H</sub> and V<sub>L</sub> domains have evolved to be paired with one another, occluding a hydrophobic surface between the two domains. We expect that such challenges are much less of a problem for protein domains that naturally exist as soluble monomers such as camelid and shark sdAbs and non-antibody scaffolds (e.g., FN3 and SH3 domains). Some camelid V<sub>H</sub>Hs rely on CDR residues for solubility as well (<xref ref-type="bibr" rid="B57">57</xref>), albeit likely to a lesser extent due to the presence of solubility-enhancing FR2 residues. One obvious explanation for the previously described bias toward negatively charged residues resulting in acidic overall pIs of V<sub>H</sub>/V<sub>L</sub> sdAbs (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B12">12</xref>), especially in CDR1 and CDR2 (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>), is that this may enhance solubility and aggregation resistance. The role of charge and negative charge in particular in solubilizing V<sub>H</sub>/V<sub>L</sub> sdAbs with hydrophobic CDRs has been previously demonstrated (<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B59">59</xref>), and appears to be highly position and scaffold dependent (<xref ref-type="bibr" rid="B4">4</xref>). Bias in favor of His residues is less easy to explain, although its imidazole side chain may also have stabilizing and solubilizing effects near physiological pH (<xref ref-type="bibr" rid="B60">60</xref>). Notably, &#x0201C;camelized&#x0201D; human V<sub>H</sub> sdAbs and human V<sub>H</sub>/V<sub>L</sub> sdAbs selected <italic>in vitro</italic> to bear solubility-promoting FR substitutions (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B61">61</xref>), may not be subject to the same stability-sequence diversity tradeoffs. We caution that although the growth advantages conferred by V<sub>H</sub>/V<sub>L</sub> sdAbs with the most stable and soluble CDR sequences were most apparent using helper phage rescue of phagemid libraries, forcing pIII-sdAb expression using hyper phage rescue or by using phage (not phagemid) or yeast display systems would not be expected to circumvent the issue of bias; instead, it might be expected to result in immediate loss of a large population of V<sub>H</sub>/V<sub>L</sub> sdAbs with poorly stable and soluble CDR sequences.</p>
<p>In conclusion, we have described three novel synthetic human V<sub>H</sub>/V<sub>L</sub> sdAb libraries as well as antigen-specific binders against a variety of target antigens selected from these libraries. Future work will seek to better understand the constraints imposed on human V<sub>H</sub>/V<sub>L</sub> sdAbs by stability-sequence diversity tradeoffs, and whether it is possible to circumvent them by <italic>in vitro</italic> engineering of human autonomous immunoglobulin variable domain folds. One possibility would be to identify and fix a minimal set of stability-enhancing CDR residues in human V<sub>H</sub>/V<sub>L</sub> sdAb libraries, which might allow for more effective randomization of the remaining CDR positions. However, doing so without significant divergence from human germline IGHV sequences, increasing the risk of immunogenicity, may be very challenging.</p>
</sec>
<sec id="S5" sec-type="author-contributor">
<title>Author Contributions</title>
<p>DK, HK, and JT isolated and characterized human V<sub>H</sub>/V<sub>L</sub> sdAb scaffolds and conducted CDR-shuffling experiments and designed the libraries. JS conducted SEC-MALS experiments. ML, HK, and KH isolated and characterized antigen-specific sdAbs. ML and KH conceived and carried out stability selections and next-generation DNA sequencing analyses. QY, GH, and CRM designed, carried out, and analyzed surface plasmon resonance experiments. KH and GH made the figures and KH wrote the manuscript. All authors read and approved the final manuscript.</p>
</sec>
<sec id="S6">
<title>Conflict of Interest Statement</title>
<p>JT and DK are inventors of US patents 8293233B2 and 9371371B2 as well as other patents and patent applications governing human V<sub>H</sub>/V<sub>L</sub> sdAb scaffolds.</p>
</sec>
</body>
<back>
<ack>
<p>We gratefully acknowledge the excellent technical help of Camille Hebert-Martineau, Sonia Leclerc, Hongtao Qi, Ken Chan, Shannon Ryan, and Julie Champagne.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This work was supported by funding from the National Research Council Canada.</p></fn>
</fn-group>
<sec id="S7" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at <uri xlink:href="http://www.frontiersin.org/articles/10.3389/fimmu.2017.01759/full&#x00023;supplementary-material">http://www.frontiersin.org/articles/10.3389/fimmu.2017.01759/full&#x00023;supplementary-material</uri>.</p>
<supplementary-material xlink:href="data_sheet_1.pdf" id="SM1" mimetype="applicationn/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname> <given-names>ES</given-names></name> <name><surname>Gussow</surname> <given-names>D</given-names></name> <name><surname>Griffiths</surname> <given-names>AD</given-names></name> <name><surname>Jones</surname> <given-names>PT</given-names></name> <name><surname>Winter</surname> <given-names>G</given-names></name></person-group>. <article-title>Binding activities of a repertoire of single immunoglobulin variable domains secreted from <italic>Escherichia coli</italic></article-title>. <source>Nature</source> (<year>1989</year>) <volume>341</volume>:<fpage>544</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1038/341544a0</pub-id><pub-id pub-id-type="pmid">2677748</pub-id></citation></ref>
<ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamers-Casterman</surname> <given-names>C</given-names></name> <name><surname>Atarhouch</surname> <given-names>T</given-names></name> <name><surname>Muyldermans</surname> <given-names>S</given-names></name> <name><surname>Robinson</surname> <given-names>G</given-names></name> <name><surname>Hamers</surname> <given-names>C</given-names></name> <name><surname>Songa</surname> <given-names>EB</given-names></name> <etal/></person-group> <article-title>Naturally occurring antibodies devoid of light chains</article-title>. <source>Nature</source> (<year>1993</year>) <volume>363</volume>:<fpage>446</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/363446a0</pub-id><pub-id pub-id-type="pmid">8502296</pub-id></citation></ref>
<ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname> <given-names>AS</given-names></name> <name><surname>Avila</surname> <given-names>D</given-names></name> <name><surname>Hughes</surname> <given-names>M</given-names></name> <name><surname>Hughes</surname> <given-names>A</given-names></name> <name><surname>McKinney</surname> <given-names>EC</given-names></name> <name><surname>Flajnik</surname> <given-names>MF</given-names></name></person-group>. <article-title>A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks</article-title>. <source>Nature</source> (<year>1995</year>) <volume>374</volume>:<fpage>168</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1038/374168a0</pub-id><pub-id pub-id-type="pmid">7877689</pub-id></citation></ref>
<ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>DY</given-names></name> <name><surname>Hussack</surname> <given-names>G</given-names></name> <name><surname>Kandalaft</surname> <given-names>H</given-names></name> <name><surname>Tanha</surname> <given-names>J</given-names></name></person-group>. <article-title>Mutational approaches to improve the biophysical properties of human single-domain antibodies</article-title>. <source>Biochim Biophys Acta</source> (<year>2014</year>) <volume>1844</volume>:<fpage>1983</fpage>&#x02013;<lpage>2001</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbapap.2014.07.008</pub-id><pub-id pub-id-type="pmid">25065345</pub-id></citation></ref>
<ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanha</surname> <given-names>J</given-names></name> <name><surname>Nguyen</surname> <given-names>TD</given-names></name> <name><surname>Ng</surname> <given-names>A</given-names></name> <name><surname>Ryan</surname> <given-names>S</given-names></name> <name><surname>Ni</surname> <given-names>F</given-names></name> <name><surname>MacKenzie</surname> <given-names>R</given-names></name></person-group>. <article-title>Improving solubility and refolding efficiency of human V<sub>H</sub>s by a novel mutational approach</article-title>. <source>Protein Eng Des Sel</source> (<year>2006</year>) <volume>19</volume>:<fpage>503</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1093/protein/gzl037</pub-id></citation></ref>
<ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanha</surname> <given-names>J</given-names></name> <name><surname>Xu</surname> <given-names>P</given-names></name> <name><surname>Chen</surname> <given-names>Z</given-names></name> <name><surname>Ni</surname> <given-names>F</given-names></name> <name><surname>Kaplan</surname> <given-names>H</given-names></name> <name><surname>Narang</surname> <given-names>SA</given-names></name> <etal/></person-group> <article-title>Optimal design features of camelized human single-domain antibody libraries</article-title>. <source>J Biol Chem</source> (<year>2001</year>) <volume>276</volume>:<fpage>24774</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M100770200</pub-id><pub-id pub-id-type="pmid">11335716</pub-id></citation></ref>
<ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname> <given-names>J</given-names></name> <name><surname>Riechmann</surname> <given-names>L</given-names></name></person-group>. <article-title>Single antibody domains as small recognition units: design and <italic>in vitro</italic> antigen selection of camelized, human V<sub>H</sub> domains with improved protein stability</article-title>. <source>Protein Eng</source> (<year>1996</year>) <volume>9</volume>:<fpage>531</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1093/protein/9.6.531</pub-id><pub-id pub-id-type="pmid">8862554</pub-id></citation></ref>
<ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname> <given-names>J</given-names></name> <name><surname>Riechmann</surname> <given-names>L</given-names></name></person-group>. <article-title>Antibody V<sub>H</sub> domains as small recognition units</article-title>. <source>Biotechnology (N Y)</source> (<year>1995</year>) <volume>13</volume>:<fpage>475</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/nbt0595-475</pub-id><pub-id pub-id-type="pmid">9634788</pub-id></citation></ref>
<ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>X</given-names></name> <name><surname>Barthelemy</surname> <given-names>PA</given-names></name> <name><surname>Rouge</surname> <given-names>L</given-names></name> <name><surname>Wiesmann</surname> <given-names>C</given-names></name> <name><surname>Sidhu</surname> <given-names>SS</given-names></name></person-group>. <article-title>Design of synthetic autonomous V<sub>H</sub> domain libraries and structural analysis of a V<sub>H</sub> domain bound to vascular endothelial growth factor</article-title>. <source>J Mol Biol</source> (<year>2013</year>) <volume>425</volume>:<fpage>2247</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="doi">10.1016/j.jmb.2013.03.020</pub-id><pub-id pub-id-type="pmid">23507309</pub-id></citation></ref>
<ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dudgeon</surname> <given-names>K</given-names></name> <name><surname>Famm</surname> <given-names>K</given-names></name> <name><surname>Christ</surname> <given-names>D</given-names></name></person-group>. <article-title>Sequence determinants of protein aggregation in human V<sub>H</sub> domains</article-title>. <source>Protein Eng Des Sel</source> (<year>2009</year>) <volume>22</volume>:<fpage>217</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1093/protein/gzn059</pub-id><pub-id pub-id-type="pmid">18957405</pub-id></citation></ref>
<ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dudgeon</surname> <given-names>K</given-names></name> <name><surname>Rouet</surname> <given-names>R</given-names></name> <name><surname>Kokmeijer</surname> <given-names>I</given-names></name> <name><surname>Schofield</surname> <given-names>P</given-names></name> <name><surname>Stolp</surname> <given-names>J</given-names></name> <name><surname>Langley</surname> <given-names>D</given-names></name> <etal/></person-group> <article-title>General strategy for the generation of human antibody variable domains with increased aggregation resistance</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2012</year>) <volume>109</volume>:<fpage>10879</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1202866109</pub-id></citation></ref>
<ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arbabi-Ghahroudi</surname> <given-names>M</given-names></name> <name><surname>To</surname> <given-names>R</given-names></name> <name><surname>Gaudette</surname> <given-names>N</given-names></name> <name><surname>Hirama</surname> <given-names>T</given-names></name> <name><surname>Ding</surname> <given-names>W</given-names></name> <name><surname>MacKenzie</surname> <given-names>R</given-names></name> <etal/></person-group> <article-title>Aggregation-resistant V<sub>H</sub>s selected by <italic>in vitro</italic> evolution tend to have disulfide-bonded loops and acidic isoelectric points</article-title>. <source>Protein Eng Des Sel</source> (<year>2009</year>) <volume>22</volume>:<fpage>59</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1093/protein/gzn071</pub-id><pub-id pub-id-type="pmid">19033278</pub-id></citation></ref>
<ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Christ</surname> <given-names>D</given-names></name> <name><surname>Famm</surname> <given-names>K</given-names></name> <name><surname>Winter</surname> <given-names>G</given-names></name></person-group>. <article-title>Repertoires of aggregation-resistant human antibody domains</article-title>. <source>Protein Eng Des Sel</source> (<year>2007</year>) <volume>20</volume>:<fpage>413</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1093/protein/gzm037</pub-id><pub-id pub-id-type="pmid">17720749</pub-id></citation></ref>
<ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Christ</surname> <given-names>D</given-names></name> <name><surname>Famm</surname> <given-names>K</given-names></name> <name><surname>Winter</surname> <given-names>G</given-names></name></person-group>. <article-title>Tapping diversity lost in transformations &#x02013; <italic>in vitro</italic> amplification of ligation reactions</article-title>. <source>Nucleic Acids Res</source> (<year>2006</year>) <volume>34</volume>:<fpage>e108</fpage>.<pub-id pub-id-type="doi">10.1093/nar/gkl605</pub-id></citation></ref>
<ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Bernardis</surname> <given-names>F</given-names></name> <name><surname>Liu</surname> <given-names>H</given-names></name> <name><surname>O&#x02019;Mahony</surname> <given-names>R</given-names></name> <name><surname>La Valle</surname> <given-names>R</given-names></name> <name><surname>Bartollino</surname> <given-names>S</given-names></name> <name><surname>Sandini</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Human domain antibodies against virulence traits of <italic>Candida albicans</italic> inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis</article-title>. <source>J Infect Dis</source> (<year>2007</year>) <volume>195</volume>:<fpage>149</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1086/509891</pub-id><pub-id pub-id-type="pmid">17152019</pub-id></citation></ref>
<ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinelli</surname> <given-names>DF</given-names></name> <name><surname>Wagener</surname> <given-names>ME</given-names></name> <name><surname>Liu</surname> <given-names>D</given-names></name> <name><surname>Yamniuk</surname> <given-names>A</given-names></name> <name><surname>Tamura</surname> <given-names>J</given-names></name> <name><surname>Grant</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>An anti-CD154 domain antibody prolongs graft survival and induces Foxp3(&#x0002B;) iTreg in the absence and presence of CTLA-4 Ig</article-title>. <source>Am J Transplant</source> (<year>2013</year>) <volume>13</volume>:<fpage>3021</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1111/ajt.12417</pub-id><pub-id pub-id-type="pmid">24007441</pub-id></citation></ref>
<ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suchard</surname> <given-names>SJ</given-names></name> <name><surname>Davis</surname> <given-names>PM</given-names></name> <name><surname>Kansal</surname> <given-names>S</given-names></name> <name><surname>Stetsko</surname> <given-names>DK</given-names></name> <name><surname>Brosius</surname> <given-names>R</given-names></name> <name><surname>Tamura</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>191</volume>:<fpage>4599</fpage>&#x02013;<lpage>610</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1300470</pub-id><pub-id pub-id-type="pmid">24081989</pub-id></citation></ref>
<ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamniuk</surname> <given-names>AP</given-names></name> <name><surname>Suri</surname> <given-names>A</given-names></name> <name><surname>Krystek</surname> <given-names>SR</given-names></name> <name><surname>Tamura</surname> <given-names>J</given-names></name> <name><surname>Ramamurthy</surname> <given-names>V</given-names></name> <name><surname>Kuhn</surname> <given-names>R</given-names></name> <etal/></person-group> <article-title>Functional antagonism of human CD40 achieved by targeting a unique species-specific epitope</article-title>. <source>J Mol Biol</source> (<year>2016</year>) <volume>428</volume>:<fpage>2860</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="doi">10.1016/j.jmb.2016.05.014</pub-id><pub-id pub-id-type="pmid">27216500</pub-id></citation></ref>
<ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname> <given-names>A</given-names></name> <name><surname>Chung</surname> <given-names>CW</given-names></name> <name><surname>Neu</surname> <given-names>M</given-names></name> <name><surname>Burman</surname> <given-names>M</given-names></name> <name><surname>Batuwangala</surname> <given-names>T</given-names></name> <name><surname>Jones</surname> <given-names>G</given-names></name> <etal/></person-group> <article-title>Novel interaction mechanism of a domain antibody-based inhibitor of human vascular endothelial growth factor with greater potency than ranibizumab and bevacizumab and improved capacity over aflibercept</article-title>. <source>J Biol Chem</source> (<year>2016</year>) <volume>291</volume>:<fpage>5500</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M115.691162</pub-id><pub-id pub-id-type="pmid">26728464</pub-id></citation></ref>
<ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname> <given-names>JH</given-names></name> <name><surname>Yamniuk</surname> <given-names>AP</given-names></name> <name><surname>Borowski</surname> <given-names>V</given-names></name> <name><surname>Kuhn</surname> <given-names>R</given-names></name> <name><surname>Susulic</surname> <given-names>V</given-names></name> <name><surname>Rex-Rabe</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases</article-title>. <source>J Immunol</source> (<year>2014</year>) <volume>192</volume>:<fpage>4083</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1303239</pub-id><pub-id pub-id-type="pmid">24670803</pub-id></citation></ref>
<ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hussack</surname> <given-names>G</given-names></name> <name><surname>Keklikian</surname> <given-names>A</given-names></name> <name><surname>Alsughayyir</surname> <given-names>J</given-names></name> <name><surname>Hanifi-Moghaddam</surname> <given-names>P</given-names></name> <name><surname>Arbabi-Ghahroudi</surname> <given-names>M</given-names></name> <name><surname>van Faassen</surname> <given-names>H</given-names></name> <etal/></person-group> <article-title>A V<sub>L</sub> single-domain antibody library shows a high-propensity to yield non-aggregating binders</article-title>. <source>Protein Eng Des Sel</source> (<year>2012</year>) <volume>25</volume>:<fpage>313</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1093/protein/gzs014</pub-id></citation></ref>
<ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>H</given-names></name> <name><surname>Yun</surname> <given-names>S</given-names></name> <name><surname>Batuwangala</surname> <given-names>TD</given-names></name> <name><surname>Steward</surname> <given-names>M</given-names></name> <name><surname>Holmes</surname> <given-names>SD</given-names></name> <name><surname>Pan</surname> <given-names>L</given-names></name> <etal/></person-group> <article-title>A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment</article-title>. <source>Int J Cancer</source> (<year>2012</year>) <volume>131</volume>:<fpage>956</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="doi">10.1002/ijc.26427</pub-id><pub-id pub-id-type="pmid">21918971</pub-id></citation></ref>
<ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>N</given-names></name> <name><surname>Fu</surname> <given-names>H</given-names></name> <name><surname>Hewitt</surname> <given-names>SM</given-names></name> <name><surname>Dimitrov</surname> <given-names>DS</given-names></name> <name><surname>Ho</surname> <given-names>M</given-names></name></person-group>. <article-title>Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2017</year>) <volume>114</volume>:<fpage>E6623</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1706055114</pub-id><pub-id pub-id-type="pmid">28739923</pub-id></citation></ref>
<ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>M</given-names></name> <name><surname>Gao</surname> <given-names>W</given-names></name> <name><surname>Wang</surname> <given-names>R</given-names></name> <name><surname>Chen</surname> <given-names>W</given-names></name> <name><surname>Man</surname> <given-names>YG</given-names></name> <name><surname>Figg</surname> <given-names>WD</given-names></name> <etal/></person-group> <article-title>Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2013</year>) <volume>110</volume>:<fpage>E1083</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1217868110</pub-id><pub-id pub-id-type="pmid">23471984</pub-id></citation></ref>
<ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jespers</surname> <given-names>L</given-names></name> <name><surname>Schon</surname> <given-names>O</given-names></name> <name><surname>Famm</surname> <given-names>K</given-names></name> <name><surname>Winter</surname> <given-names>G</given-names></name></person-group>. <article-title>Aggregation-resistant domain antibodies selected on phage by heat denaturation</article-title>. <source>Nat Biotechnol</source> (<year>2004</year>) <volume>22</volume>:<fpage>1161</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1038/nbt1000</pub-id><pub-id pub-id-type="pmid">15300256</pub-id></citation></ref>
<ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname> <given-names>A</given-names></name> <name><surname>Dunlevy</surname> <given-names>G</given-names></name> <name><surname>Rycroft</surname> <given-names>D</given-names></name> <name><surname>Topley</surname> <given-names>P</given-names></name> <name><surname>Holt</surname> <given-names>LJ</given-names></name> <name><surname>Herbert</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon</article-title>. <source>Protein Eng Des Sel</source> (<year>2010</year>) <volume>23</volume>:<fpage>271</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1093/protein/gzp091</pub-id><pub-id pub-id-type="pmid">20093262</pub-id></citation></ref>
<ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holt</surname> <given-names>LJ</given-names></name> <name><surname>Basran</surname> <given-names>A</given-names></name> <name><surname>Jones</surname> <given-names>K</given-names></name> <name><surname>Chorlton</surname> <given-names>J</given-names></name> <name><surname>Jespers</surname> <given-names>LS</given-names></name> <name><surname>Brewis</surname> <given-names>ND</given-names></name> <etal/></person-group> <article-title>Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs</article-title>. <source>Protein Eng Des Sel</source> (<year>2008</year>) <volume>21</volume>:<fpage>283</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1093/protein/gzm067</pub-id><pub-id pub-id-type="pmid">18387938</pub-id></citation></ref>
<ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rouet</surname> <given-names>R</given-names></name> <name><surname>Dudgeon</surname> <given-names>K</given-names></name> <name><surname>Christie</surname> <given-names>M</given-names></name> <name><surname>Langley</surname> <given-names>D</given-names></name> <name><surname>Christ</surname> <given-names>D</given-names></name></person-group>. <article-title>Fully human V<sub>H</sub> single domains that rival the stability and cleft recognition of camelid antibodies</article-title>. <source>J Biol Chem</source> (<year>2015</year>) <volume>290</volume>:<fpage>11905</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M114.614842</pub-id><pub-id pub-id-type="pmid">25737448</pub-id></citation></ref>
<ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mandrup</surname> <given-names>OA</given-names></name> <name><surname>Friis</surname> <given-names>NA</given-names></name> <name><surname>Lykkemark</surname> <given-names>S</given-names></name> <name><surname>Just</surname> <given-names>J</given-names></name> <name><surname>Kristensen</surname> <given-names>P</given-names></name></person-group>. <article-title>A novel heavy domain antibody library with functionally optimized complementarity determining regions</article-title>. <source>PLoS One</source> (<year>2013</year>) <volume>8</volume>:<fpage>e76834</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0076834</pub-id><pub-id pub-id-type="pmid">24116173</pub-id></citation></ref>
<ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jespers</surname> <given-names>L</given-names></name> <name><surname>Schon</surname> <given-names>O</given-names></name> <name><surname>James</surname> <given-names>LC</given-names></name> <name><surname>Veprintsev</surname> <given-names>D</given-names></name> <name><surname>Winter</surname> <given-names>G</given-names></name></person-group>. <article-title>Crystal structure of HEL4, a soluble, refoldable human V<sub>H</sub> single domain with a germ-line scaffold</article-title>. <source>J Mol Biol</source> (<year>2004</year>) <volume>337</volume>:<fpage>893</fpage>&#x02013;<lpage>903</lpage>.<pub-id pub-id-type="doi">10.1016/j.jmb.2004.02.013</pub-id></citation></ref>
<ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname> <given-names>KA</given-names></name> <name><surname>Kandalaft</surname> <given-names>H</given-names></name> <name><surname>Lowden</surname> <given-names>MJ</given-names></name> <name><surname>Rossotti</surname> <given-names>MA</given-names></name> <name><surname>van Faassen</surname> <given-names>H</given-names></name> <name><surname>Hussack</surname> <given-names>G</given-names></name> <etal/></person-group> <article-title>A disulfide-stabilized human V<sub>L</sub> single-domain antibody library is a source of soluble and highly thermostable binders</article-title>. <source>Mol Immunol</source> (<year>2017</year>) <volume>90</volume>:<fpage>190</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.molimm.2017.07.006</pub-id><pub-id pub-id-type="pmid">28820969</pub-id></citation></ref>
<ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>GW</given-names></name> <name><surname>Vaysburd</surname> <given-names>M</given-names></name> <name><surname>Allen</surname> <given-names>MD</given-names></name> <name><surname>Settanni</surname> <given-names>G</given-names></name> <name><surname>Fersht</surname> <given-names>AR</given-names></name></person-group>. <article-title>Structure of human MDM4 N-terminal domain bound to a single-domain antibody</article-title>. <source>J Mol Biol</source> (<year>2009</year>) <volume>385</volume>:<fpage>1578</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1016/j.jmb.2008.11.043</pub-id><pub-id pub-id-type="pmid">19084022</pub-id></citation></ref>
<ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>Z</given-names></name> <name><surname>Feng</surname> <given-names>M</given-names></name> <name><surname>Gao</surname> <given-names>W</given-names></name> <name><surname>Phung</surname> <given-names>Y</given-names></name> <name><surname>Chen</surname> <given-names>W</given-names></name> <name><surname>Chaudhary</surname> <given-names>A</given-names></name> <etal/></person-group> <article-title>A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface</article-title>. <source>Mol Cancer Ther</source> (<year>2013</year>) <volume>12</volume>:<fpage>416</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0731</pub-id><pub-id pub-id-type="pmid">23371858</pub-id></citation></ref>
<ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gay</surname> <given-names>RD</given-names></name> <name><surname>Clarke</surname> <given-names>AW</given-names></name> <name><surname>Elgundi</surname> <given-names>Z</given-names></name> <name><surname>Domagala</surname> <given-names>T</given-names></name> <name><surname>Simpson</surname> <given-names>RJ</given-names></name> <name><surname>Le</surname> <given-names>NB</given-names></name> <etal/></person-group> <article-title>Anti-TNF-&#x003B1; domain antibody construct CEP-37247: full antibody functionality at half the size</article-title>. <source>MAbs</source> (<year>2010</year>) <volume>2</volume>:<fpage>625</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="doi">10.4161/mabs.2.6.13493</pub-id></citation></ref>
<ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertok</surname> <given-names>S</given-names></name> <name><surname>Wilson</surname> <given-names>MR</given-names></name> <name><surname>Morley</surname> <given-names>PJ</given-names></name> <name><surname>de Wildt</surname> <given-names>R</given-names></name> <name><surname>Bayliffe</surname> <given-names>A</given-names></name> <name><surname>Takata</surname> <given-names>M</given-names></name></person-group>. <article-title>Selective inhibition of intra-alveolar p55 TNF receptor attenuates ventilator-induced lung injury</article-title>. <source>Thorax</source> (<year>2012</year>) <volume>67</volume>:<fpage>244</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="doi">10.1136/thoraxjnl-2011-200590</pub-id><pub-id pub-id-type="pmid">22156959</pub-id></citation></ref>
<ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname> <given-names>MC</given-names></name> <name><surname>Wurthner</surname> <given-names>JU</given-names></name> <name><surname>Morley</surname> <given-names>PJ</given-names></name> <name><surname>Birchler</surname> <given-names>MA</given-names></name> <name><surname>Lambert</surname> <given-names>J</given-names></name> <name><surname>Albayaty</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>Autoantibodies to variable heavy (V<sub>H</sub>) chain Ig sequences in humans impact the safety and clinical pharmacology of a V<sub>H</sub> domain antibody antagonist of TNF-&#x003B1; receptor 1</article-title>. <source>J Clin Immunol</source> (<year>2013</year>) <volume>33</volume>:<fpage>1192</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-013-9915-0</pub-id><pub-id pub-id-type="pmid">23832582</pub-id></citation></ref>
<ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cordy</surname> <given-names>JC</given-names></name> <name><surname>Morley</surname> <given-names>PJ</given-names></name> <name><surname>Wright</surname> <given-names>TJ</given-names></name> <name><surname>Birchler</surname> <given-names>MA</given-names></name> <name><surname>Lewis</surname> <given-names>AP</given-names></name> <name><surname>Emmins</surname> <given-names>R</given-names></name> <etal/></person-group> <article-title>Specificity of human anti-variable heavy (V<sub>H</sub>) chain autoantibodies and impact on the design and clinical testing of a V<sub>H</sub> domain antibody antagonist of tumour necrosis factor-&#x003B1; receptor 1</article-title>. <source>Clin Exp Immunol</source> (<year>2015</year>) <volume>182</volume>:<fpage>139</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="doi">10.1111/cei.12680</pub-id></citation></ref>
<ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>To</surname> <given-names>R</given-names></name> <name><surname>Hirama</surname> <given-names>T</given-names></name> <name><surname>Arbabi-Ghahroudi</surname> <given-names>M</given-names></name> <name><surname>MacKenzie</surname> <given-names>R</given-names></name> <name><surname>Wang</surname> <given-names>P</given-names></name> <name><surname>Xu</surname> <given-names>P</given-names></name> <etal/></person-group> <article-title>Isolation of monomeric human V<sub>H</sub>s by a phage selection</article-title>. <source>J Biol Chem</source> (<year>2005</year>) <volume>280</volume>:<fpage>41395</fpage>&#x02013;<lpage>403</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M509900200</pub-id></citation></ref>
<ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>DY</given-names></name> <name><surname>To</surname> <given-names>R</given-names></name> <name><surname>Kandalaft</surname> <given-names>H</given-names></name> <name><surname>Ding</surname> <given-names>W</given-names></name> <name><surname>van Faassen</surname> <given-names>H</given-names></name> <name><surname>Luo</surname> <given-names>Y</given-names></name> <etal/></person-group> <article-title>Antibody light chain variable domains and their biophysically improved versions for human immunotherapy</article-title>. <source>MAbs</source> (<year>2014</year>) <volume>6</volume>:<fpage>219</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.4161/mabs.26844</pub-id><pub-id pub-id-type="pmid">24423624</pub-id></citation></ref>
<ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>DY</given-names></name> <name><surname>Kandalaft</surname> <given-names>H</given-names></name> <name><surname>Ding</surname> <given-names>W</given-names></name> <name><surname>Ryan</surname> <given-names>S</given-names></name> <name><surname>van Faassen</surname> <given-names>H</given-names></name> <name><surname>Hirama</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Disulfide linkage engineering for improving biophysical properties of human V<sub>H</sub> domains</article-title>. <source>Protein Eng Des Sel</source> (<year>2012</year>) <volume>25</volume>:<fpage>581</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1093/protein/gzs055</pub-id><pub-id pub-id-type="pmid">22942392</pub-id></citation></ref>
<ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Virnekas</surname> <given-names>B</given-names></name> <name><surname>Ge</surname> <given-names>L</given-names></name> <name><surname>Pluckthun</surname> <given-names>A</given-names></name> <name><surname>Schneider</surname> <given-names>KC</given-names></name> <name><surname>Wellnhofer</surname> <given-names>G</given-names></name> <name><surname>Moroney</surname> <given-names>SE</given-names></name></person-group>. <article-title>Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis</article-title>. <source>Nucleic Acids Res</source> (<year>1994</year>) <volume>22</volume>:<fpage>5600</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1093/nar/22.25.5600</pub-id><pub-id pub-id-type="pmid">7838712</pub-id></citation></ref>
<ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baral</surname> <given-names>TN</given-names></name> <name><surname>MacKenzie</surname> <given-names>R</given-names></name> <name><surname>Arbabi Ghahroudi</surname> <given-names>M</given-names></name></person-group>. <article-title>Single-domain antibodies and their utility</article-title>. <source>Curr Protoc Immunol</source> (<year>2013</year>) <volume>103</volume>:<fpage>Unit 2.17</fpage>.<pub-id pub-id-type="doi">10.1002/0471142735.im0217s103</pub-id><pub-id pub-id-type="pmid">24510545</pub-id></citation></ref>
<ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dorion-Thibaudeau</surname> <given-names>J</given-names></name> <name><surname>St-Laurent</surname> <given-names>G</given-names></name> <name><surname>Raymond</surname> <given-names>C</given-names></name> <name><surname>De Crescenzo</surname> <given-names>G</given-names></name> <name><surname>Durocher</surname> <given-names>Y</given-names></name></person-group>. <article-title>Biotinylation of the Fc&#x003B3; receptor ectodomains by mammalian cell co-transfection: application to the development of a surface plasmon resonance-based assay</article-title>. <source>J Mol Recognit</source> (<year>2016</year>) <volume>29</volume>:<fpage>60</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1002/jmr.2495</pub-id></citation></ref>
<ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname> <given-names>KA</given-names></name> <name><surname>Hussack</surname> <given-names>G</given-names></name> <name><surname>Collins</surname> <given-names>C</given-names></name> <name><surname>Zwaagstra</surname> <given-names>JC</given-names></name> <name><surname>Tanha</surname> <given-names>J</given-names></name> <name><surname>MacKenzie</surname> <given-names>CR</given-names></name></person-group>. <article-title>Isolation of TGF-&#x003B2;-neutralizing single-domain antibodies of predetermined epitope specificity using next-generation DNA sequencing</article-title>. <source>Protein Eng Des Sel</source> (<year>2016</year>) <volume>29</volume>:<fpage>439</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1093/protein/gzw043</pub-id></citation></ref>
<ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname> <given-names>KA</given-names></name> <name><surname>Tanha</surname> <given-names>J</given-names></name> <name><surname>Hussack</surname> <given-names>G</given-names></name></person-group>. <article-title>Identification of cross-reactive single-domain antibodies against serum albumin using next-generation DNA sequencing</article-title>. <source>Protein Eng Des Sel</source> (<year>2015</year>) <volume>28</volume>:<fpage>379</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1093/protein/gzv039</pub-id><pub-id pub-id-type="pmid">26319004</pub-id></citation></ref>
<ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname> <given-names>MC</given-names></name> <name><surname>Aulabaugh</surname> <given-names>A</given-names></name> <name><surname>Jin</surname> <given-names>G</given-names></name> <name><surname>Cowling</surname> <given-names>R</given-names></name> <name><surname>Bard</surname> <given-names>J</given-names></name> <name><surname>Malamas</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery</article-title>. <source>Anal Biochem</source> (<year>2004</year>) <volume>332</volume>:<fpage>153</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.ab.2004.04.031</pub-id><pub-id pub-id-type="pmid">15301960</pub-id></citation></ref>
<ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ericsson</surname> <given-names>UB</given-names></name> <name><surname>Hallberg</surname> <given-names>BM</given-names></name> <name><surname>Detitta</surname> <given-names>GT</given-names></name> <name><surname>Dekker</surname> <given-names>N</given-names></name> <name><surname>Nordlund</surname> <given-names>P</given-names></name></person-group>. <article-title>Thermofluor-based high-throughput stability optimization of proteins for structural studies</article-title>. <source>Anal Biochem</source> (<year>2006</year>) <volume>357</volume>:<fpage>289</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="doi">10.1016/j.ab.2006.07.027</pub-id><pub-id pub-id-type="pmid">16962548</pub-id></citation></ref>
<ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname> <given-names>KA</given-names></name> <name><surname>Sulea</surname> <given-names>T</given-names></name> <name><surname>van Faassen</surname> <given-names>H</given-names></name> <name><surname>Hussack</surname> <given-names>G</given-names></name> <name><surname>Purisima</surname> <given-names>EO</given-names></name> <name><surname>MacKenzie</surname> <given-names>CR</given-names></name> <etal/></person-group> <article-title>A rational engineering strategy for designing protein A-binding camelid single-domain antibodies</article-title>. <source>PLoS One</source> (<year>2016</year>) <volume>11</volume>:<fpage>e0163113</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0163113</pub-id><pub-id pub-id-type="pmid">27631624</pub-id></citation></ref>
<ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baral</surname> <given-names>TN</given-names></name> <name><surname>Chao</surname> <given-names>SY</given-names></name> <name><surname>Li</surname> <given-names>S</given-names></name> <name><surname>Tanha</surname> <given-names>J</given-names></name> <name><surname>Arbabi-Ghahroudi</surname> <given-names>M</given-names></name> <name><surname>Zhang</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Crystal structure of a human single domain antibody dimer formed through V<sub>H</sub>-V<sub>H</sub> non-covalent interactions</article-title>. <source>PLoS One</source> (<year>2012</year>) <volume>7</volume>:<fpage>e30149</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0030149</pub-id></citation></ref>
<ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sepulveda</surname> <given-names>J</given-names></name> <name><surname>Jin</surname> <given-names>H</given-names></name> <name><surname>Sblattero</surname> <given-names>D</given-names></name> <name><surname>Bradbury</surname> <given-names>A</given-names></name> <name><surname>Burrone</surname> <given-names>OR</given-names></name></person-group>. <article-title>Binders based on dimerised immunoglobulin V<sub>H</sub> domains</article-title>. <source>J Mol Biol</source> (<year>2003</year>) <volume>333</volume>:<fpage>355</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1016/j.jmb.2003.08.033</pub-id><pub-id pub-id-type="pmid">14529622</pub-id></citation></ref>
<ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>H</given-names></name> <name><surname>Sepulveda</surname> <given-names>J</given-names></name> <name><surname>Burrone</surname> <given-names>OR</given-names></name></person-group>. <article-title>Selection and characterisation of binders based on homodimerisation of immunoglobulin V<sub>H</sub> domains</article-title>. <source>FEBS Lett</source> (<year>2003</year>) <volume>554</volume>:<fpage>323</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/S0014-5793(03)01182-7</pub-id></citation></ref>
<ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname> <given-names>H</given-names></name> <name><surname>Sepulveda</surname> <given-names>J</given-names></name> <name><surname>Burrone</surname> <given-names>OR</given-names></name></person-group>. <article-title>Specific recognition of a dsDNA sequence motif by an immunoglobulin V<sub>H</sub> homodimer</article-title>. <source>Protein Sci</source> (<year>2004</year>) <volume>13</volume>:<fpage>3222</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1110/ps.04921704</pub-id><pub-id pub-id-type="pmid">15557264</pub-id></citation></ref>
<ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>Y</given-names></name> <name><surname>Batyuk</surname> <given-names>A</given-names></name> <name><surname>Honegger</surname> <given-names>A</given-names></name> <name><surname>Brandl</surname> <given-names>F</given-names></name> <name><surname>Mittl</surname> <given-names>PRE</given-names></name> <name><surname>Pl&#x000FC;ckthun</surname> <given-names>A</given-names></name></person-group>. <article-title>Rigidly connected multispecific artificial binders with adjustable geometries</article-title>. <source>Sci Rep</source> (<year>2017</year>) <volume>7</volume>:<fpage>11217</fpage>.<pub-id pub-id-type="doi">10.1038/s41598-017-11472-x</pub-id><pub-id pub-id-type="pmid">28894181</pub-id></citation></ref>
<ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drabek</surname> <given-names>D</given-names></name> <name><surname>Janssens</surname> <given-names>R</given-names></name> <name><surname>de Boer</surname> <given-names>E</given-names></name> <name><surname>Rademaker</surname> <given-names>R</given-names></name> <name><surname>Kloess</surname> <given-names>J</given-names></name> <name><surname>Skehel</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Expression cloning and production of human heavy-chain-only antibodies from murine transgenic plasma cells</article-title>. <source>Front Immunol</source> (<year>2016</year>) <volume>7</volume>:<fpage>619</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2016.00619</pub-id><pub-id pub-id-type="pmid">28066429</pub-id></citation></ref>
<ref id="B55"><label>55</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Br&#x000FC;ggemann</surname> <given-names>M</given-names></name> <name><surname>Zou</surname> <given-names>X</given-names></name></person-group>, Inventors; <publisher-name>Crescendo Biologics Ltd.</publisher-name>, Assignee. <source>Mouse &#x003BB; Light Chain Locus</source>. United States patent US 9439405 B2 (<year>2016</year>).</citation></ref>
<ref id="B56"><label>56</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Gallo</surname> <given-names>M</given-names></name> <name><surname>Kang</surname> <given-names>JS</given-names></name> <name><surname>Pigott</surname> <given-names>CR</given-names></name></person-group>, Inventors; <publisher-name>Innovative Targeting Solutions, Inc.</publisher-name>, Assignee. <source>Sequence Diversity Generation in Immunoglobulins</source>. United States patent US 8012714 B2 (<year>2011</year>).</citation></ref>
<ref id="B57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conrath</surname> <given-names>K</given-names></name> <name><surname>Vincke</surname> <given-names>C</given-names></name> <name><surname>Stijlemans</surname> <given-names>B</given-names></name> <name><surname>Schymkowitz</surname> <given-names>J</given-names></name> <name><surname>Decanniere</surname> <given-names>K</given-names></name> <name><surname>Wyns</surname> <given-names>L</given-names></name> <etal/></person-group> <article-title>Antigen binding and solubility effects upon the veneering of a camel V<sub>H</sub>H in framework-2 to mimic a V<sub>H</sub></article-title>. <source>J Mol Biol</source> (<year>2005</year>) <volume>350</volume>:<fpage>112</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1016/j.jmb.2005.04.050</pub-id><pub-id pub-id-type="pmid">15913651</pub-id></citation></ref>
<ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perchiacca</surname> <given-names>JM</given-names></name> <name><surname>Ladiwala</surname> <given-names>AR</given-names></name> <name><surname>Bhattacharya</surname> <given-names>M</given-names></name> <name><surname>Tessier</surname> <given-names>PM</given-names></name></person-group>. <article-title>Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions</article-title>. <source>Protein Eng Des Sel</source> (<year>2012</year>) <volume>25</volume>:<fpage>591</fpage>&#x02013;<lpage>601</lpage>.<pub-id pub-id-type="doi">10.1093/protein/gzs042</pub-id><pub-id pub-id-type="pmid">22843678</pub-id></citation></ref>
<ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perchiacca</surname> <given-names>JM</given-names></name> <name><surname>Lee</surname> <given-names>CC</given-names></name> <name><surname>Tessier</surname> <given-names>PM</given-names></name></person-group>. <article-title>Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold</article-title>. <source>Protein Eng Des Sel</source> (<year>2014</year>) <volume>27</volume>:<fpage>29</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1093/protein/gzt058</pub-id><pub-id pub-id-type="pmid">24398633</pub-id></citation></ref>
<ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>P</given-names></name> <name><surname>Warwicker</surname> <given-names>J</given-names></name></person-group>. <article-title>Evidence for the adaptation of protein pH-dependence to subcellular pH</article-title>. <source>BMC Biol</source> (<year>2009</year>) <volume>7</volume>:<fpage>69</fpage>.<pub-id pub-id-type="doi">10.1186/1741-7007-7-69</pub-id><pub-id pub-id-type="pmid">19849832</pub-id></citation></ref>
<ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barthelemy</surname> <given-names>PA</given-names></name> <name><surname>Raab</surname> <given-names>H</given-names></name> <name><surname>Appleton</surname> <given-names>BA</given-names></name> <name><surname>Bond</surname> <given-names>CJ</given-names></name> <name><surname>Wu</surname> <given-names>P</given-names></name> <name><surname>Wiesmann</surname> <given-names>C</given-names></name> <etal/></person-group> <article-title>Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains</article-title>. <source>J Biol Chem</source> (<year>2008</year>) <volume>283</volume>:<fpage>3639</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M708536200</pub-id><pub-id pub-id-type="pmid">18045863</pub-id></citation></ref>
</ref-list>
</back>
</article>
